Medallia Announces Timing of Third Quarter 2021 Financial Results

Medallia Announces Timing of Third Quarter 2021 Financial Results

SAN FRANCISCO–(BUSINESS WIRE)–
Medallia Inc. (NYSE: MDLA), the global leader in experience management, today announced that it will report financial results for the third quarter of fiscal year 2021 on Thursday, December 3, 2020 after the market close. Medallia will host a conference call to discuss the results at 1:30 p.m. PT on the same day.

What: Medallia Third Quarter of Fiscal Year 2021 Financial Results Conference Call

When: Thursday, December 3, 2020 at 1:30 p.m. PT (4:30 p.m. ET)

Webcast link: https://investor.medallia.com/events-and-presentations

Replay: A webcast replay will be available on the Investor Relations section of our website under the Events & Presentations page.

About Medallia

Medallia (NYSE: MDLA) is the pioneer and market leader in Experience Management. Medallia’s award-winning SaaS platform, the Medallia Experience Cloud, leads the market in the understanding and management of experience for customers, employees and citizens. Medallia captures experience signals created on daily journeys in person, on calls and digital channels, over video and social media and IoT interactions and applies proprietary AI technology to reveal personalized and predictive insights that can drive action with tremendous business results. Using Medallia Experience Cloud, customers can reduce churn, turn detractors into promoters and buyers, create in-the-moment cross-sell and up-sell opportunities and drive revenue-impacting business decisions, providing clear and potent returns on investment.

www.medallia.com

© 2020 Medallia, Inc. All rights reserved. Medallia®, the Medallia logo, and the names and marks associated with Medallia’s products are trademarks of Medallia. All other trademarks are the property of their respective owners.

Investor Contact:

Carolyn Bass

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Data Management Technology Mobile/Wireless Software Networks Internet

MEDIA:

Logo
Logo

Globus Medical Announces First Surgeries with ExcelsiusGPS® Interbody Solutions

New ExcelsiusGPS® Interbody Solutions module expands system for planning and navigating the entire interbody fusion procedure

AUDUBON, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that Dr. Sheeraz Qureshi (Hospital for Special Surgery, New York, NY) and Dr. Paul Park (University of Michigan, Ann Arbor, MI) were the first surgeons to utilize the ExcelsiusGPS® Interbody Solutions module. Dr. Qureshi performed a robotic navigated transforaminal lumbar interbody (TLIF) fusion and Dr. Park executed a robotic navigated single position lateral interbody fusion procedure, both using the ExcelsiusGPS® robotic navigation system.

Enhanced utility and efficiency further define ExcelsiusGPS® as the leader in spinal robotics. The system delivers best-in-class responsiveness through next generation software, advanced merging capabilities, and faster robotic arm movement. With the use of navigated instruments to target planned interbody trajectories and optimal port or retractor placement, ExcelsiusGPS® Interbody Solutions seamlessly improves surgeon workflow. “I am very excited for the newest evolution of the ExcelsiusGPS® platform,” said Dr. Sheeraz Qureshi. “This update provides advanced solutions for interbody placement using a robotic navigation platform that do not currently exist.”

ExcelsiusGPS® Interbody Solutions is changing what computer-assisted surgery means for surgeons globally. Surgery with ExcelsiusGPS® has evolved from planning and placing pedicle screws to helping surgeons perform robotic navigated TLIF and LLIF procedures from start to finish. Surgeons can now seamlessly navigate disc preparation, trialing, and interbody insertion through a rigid arm-mounted retractor. ExcelsiusGPS® Interbody Solutions allows for fine-tuned interbody planning of implant size and position with exceptional 3D visibility. Visualizing the implant plan while navigating instruments and implants may help surgeons better achieve surgery goals and execute plans, level by level. As Dr. Paul Park remarked, “The advanced planning and ability of the robot to impact surgery beyond screw placement makes Interbody Solutions the next step forward in the evolution of robotic spinal surgery.”

Globus Medical’s ExcelsiusGPS® is designed to enhance the safety, accuracy, and operating room efficiency of spinal surgery. Every day, this revolutionary platform is helping surgeons and hospitals globally provide the best possible treatment options for their patients. Now, the best-in-class robotic navigation system advancing spine surgery just got better with ExcelsiusGPS® Interbody Solutions.

Visit www.globusmedical.com/interbodysolutions to learn more.

About Globus Medical, Inc.

Globus Medical, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at http://www.globusmedical.com.

Safe Harbor Statements

All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with changing laws and regulations that are applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Contact:

Brian Kearns
Senior Vice President, Business Development and Investor Relations
Phone: (610) 930-1800
Email: [email protected]
www.globusmedical.com

CDK Global Declares Regular Quarterly Cash Dividend

HOFFMAN ESTATES, Ill., Nov. 12, 2020 (GLOBE NEWSWIRE) — CDK Global, Inc. (NASDAQ:CDK) has declared a regular quarterly cash dividend of $0.15 per share payable on December 30, 2020 to shareholders of record at the close of business on December 1, 2020.

About CDK Global

With $2 billion in revenues, CDK Global (NASDAQ:CDK) is a leading global provider of integrated information technology solutions to the automotive retail and adjacent industries. Focused on enabling end-to-end automotive commerce, CDK Global provides solutions to dealers in more than 100 countries around the world, serving approximately 30,000 retail locations and most automotive manufacturers. CDK solutions automate and integrate all parts of the dealership and buying process, including the acquisition, sale, financing, insuring, parts supply, repair and maintenance of vehicles. Visit cdkglobal.com.

Contacts:

Investor Relations Contact:

Julie Schlueter
847.485.4643
[email protected]

Media Contact:

Roxanne Pipitone
847.485.4423
[email protected] 

ERYTECH to Present at Jefferies Virtual Healthcare Conference

LYON, France and CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) — ERYTECH Pharma (Nasdaq & Euronext: ERYP),announced today that its CEO, Gil Beyen, will present an update at the Jefferies Virtual London Healthcare Conference at 12:00pm EST / 05:00pm GMT / 6:00pm CET on November 18, 2020.

A webcast of the event will be available on ERYTECH’s website at www.erytech.com/investors/webcast/

About ERYTECH and eryaspase

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in acute lymphoblastic leukemia is ongoing in the Nordic countries of Europe.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable,
EnterNext
PEA-PME 150 and Next Biotech indexes.        

For more information, please visit

www.erytech.com
        

CONTACTS

ERYTECH                     
Eric Soyer
CFO & COO
LifeSci Advisors, LLC

Investor Relations
Corey Davis, Ph.D.

NewCap

Mathilde Bohin /

Louis-Victor Delouvrier

Investor relations
Nicolas Merigeau
Media relations

+33 4 78 74 44 38
[email protected] 


+1 (212) 915 – 2577
[email protected]

+33 1 44 71 94 94
[email protected] 

PDF available at: http://ml.globenewswire.com/Resource/Download/2f6d2e16-6591-4b5f-9d7b-d3324e3dde89

Guardian Capital Group Limited (TSX: GCG; GCG.A) Announces 2020 Third Quarter Operating Results

TORONTO, Nov. 12, 2020 (GLOBE NEWSWIRE) —

All per share figures disclosed below are stated on a diluted basis.

         
For the periods ended September 30 Three months
Nine months
($ in thousands, except per share amounts)   2020   2019     2020     2019
         
Net revenue $ 52,042 $ 45,983   $ 152,067   $ 136,237
Operating earnings   12,108   12,105     36,348     35,871
Net gains (losses)   35,739   (1,274 )   (82,296 )   72,566
Net earnings (loss) attributable to shareholders   42,201   8,275     (43,681 )   92,333
         
         
EBITDA(1) $ 16,238 $ 16,036   $ 47,910   $ 46,783
Adjusted cash flow from operations(1)   10,507   13,053     39,230     36,081
         
         
Per share:        
Net earnings (loss) attributable to shareholders $ 1.56 $ 0.31   $ (1.72 ) $ 3.37
EBITDA(1)   0.60   0.59     1.78     1.72
Adjusted cash flow from operations(1)   0.39   0.48     1.46     0.33
         
         
         
As at     2020     2019  
($ in millions, except per share amounts)   September 30


  December 31   September 30
         
Assets under management   $ 32,734   $ 31,147   $ 30,243
Assets under administration     20,755     20,248     19,040
Shareholders’ equity     632     683     654
Securities     552     682     664
         
Per share:                    
Shareholders’ equity(1)   $ 23.25   $ 25.01   $ 23.93
Securities(1)     20.30
    24.99     24.30
         

The Company is reporting Operating earnings of $12.1 million for the quarter ended September 30, 2020, substantially unchanged from the $12.1 million reported in the third quarter of 2019.

The Net revenue for the current quarter grew to $52.0 million, $6.0 million or 13% higher than the $46.0 million reported in the same quarter in the prior year. Excluding the revenue contributions of $2.0 million from Aurrea Signature Inc. (“Aurrea”), and Modern Advisor Canada Inc. (“Modern Advisor”), two businesses which were acquired subsequent to the third quarter of 2019, the growth in Net revenue was $3.0 million. This organic growth was largely driven by growth in Guardcap Investment Management (“GuardCap”), the UK investment management subsidiary and IDC Worldsource Insurance Network (“IDC WIN”), the life insurance managing general agency subsidiary.   

Expenses in the current quarter were $39.9 million, a $6.0 million increase from $33.9 million in the same quarter in the prior year. Included in the current quarter’s expenses are the expenses of Aurrea, Modern Advisor and those involved with the expansion of the Canadian Retail Asset Management team, which is focused on providing investment solutions for the Canadian retail market. The total expenses associated with these three businesses were $2.9 million in the current quarter.

The Company’s assets under management (“AUM”) reached $32.7 billion as at September 30, 2020, a 5% increase from $31.1 billion as at December 31, 2019, and an 8% increase from $30.2 billion as at September 30, 2019. The continued recovery in the global financial markets and the significant inflow of assets experienced by GuardCap drove the growth in AUM during the current quarter. The AUM managed by GuardCap has grown to $8.0 billion by the end of the current quarter from $4.0 billion at the end of 2019.

The Company’s assets under administration (“AUA”) were $20.8 billion as at September 30, 2020, compared to $20.2 billion at the end of 2019 and $19.0 billion as at September 30, 2019. Included as at September 30, 2020 were $0.5 billion of AUA provided by Aurrea.

The global financial markets experienced continued recoveries during the third quarter from the significant decline in the first quarter, resulting in Net gains of $35.7 million for the current quarter, compared to Net losses of $1.3 million in the same quarter in the prior year.

As a result of the Net gains and Operating earnings described above, the Company’s Net earnings attributable to shareholders in the current quarter were $42.2 million, compared to $8.3 million in the same quarter in 2019.  

EBITDA(1) for the current quarter was $16.2 million, compared to $16.0 million in the same period in the prior year. Adjusted cash flow from operations(1) for the current quarter was $10.5 million, compared to $13.1 million in the same quarter in the prior year. The lower Adjusted cash flow from operations was due to significant tax installments being paid in the current quarter, compared to the prior year.

The Company’s Shareholders’ equity as at September 30, 2020 was $632 million, or $23.25 per share(1), compared to $683 million, or $25.01 per share(1) as at December 31, 2019, and $654 million or $23.93 per share(1) as at September 30, 2019.

As the global equity markets continued to recover in the current quarter, the fair value of the Company’s Securities experienced a continued increase in fair value. However, the fair value of the Company’s Securities are less than the December 31, 2019 value due to the disposal of a portion of the holdings of the Bank of Montreal (“BMO”) shares in the first half of the year and the current share price of BMO remaining below December 31, 2019 value. The fair value of the Company’s Securities as at September 30, 2020 was $552 million, or $20.30 per share(1), compared to $682 million, or $24.99 per share(1) as at December 31, 2019 and $664 million or $24.30 per share(1) as at September 30, 2019.

The Board of Directors has declared a quarterly eligible dividend of $0.16 per share, payable on January 18, 2021, to shareholders of record on January 11, 2021.

The Company’s financial results for the past eight quarters are summarized in the following table. All per share figures are stated on a diluted basis.

                 
  Sep 30,
2020
Jun 30,
2020
Mar 31,
2020
Dec 31,
2019
Sep 30,
2019
Jun 30,
2019
Mar 31,
2019
Dec 31,
2018
                 
                 
As at ($ in millions)                
Assets under management $
32,734
$31,196 $27,527   $31,147 $30,243   $30,088 $29,631 $26,962  
Assets under administration 20,755 20,010 18,152   20,248 19,040   18,784 18,745 17,385  
                 
                 
For the three months ended ($ in thousands)                
Net revenue $
52,042
$50,124 $49,901   $49,865 $45,983   $45,963 $44,291 $44,300  
Operating earnings 12,108 13,427 10,813   13,030 12,105   12,590 11,176 12,137  
Net gains (losses) 35,739 43,254 (161,289 ) 24,140 (1,274 ) 7,957 65,883 (89,001 )
Net earnings (loss) 42,652 51,244 (134,911 ) 31,808 8,952   17,601 68,099 (69,652 )
Net earnings (loss) attributable to shareholders 42,201 50,486 (136,368 ) 30,787 8,275   16,838 67,220 (70,449 )
                 
                 
Net earnings (loss) attributable to shareholders:              
Per Class A and Common share (in $)                
Basic $
1.66
$1.99 $(5.35 ) $1.20 $0.32   $0.65 $2.57 $(2.63 )
Diluted 1.56 1.87 (5.35 ) 1.13 0.31   0.62 2.43 (2.63 )
                 
Dividends paid (in $) $
0.160
$0.160 $0.150   $0.150 $0.150   $0.150 $0.125 $0.125  
                 
                 
As at                
Shareholders’ equity ($ in thousands) $
631,863
$596,265 $562,821   $682,777 $653,983   $647,983 $656,167 $599,311  
                 
Per Class A and Common share (1)(in $)                
Basic $
24.80
$23.50 $22.18   $26.73 $25.49   $25.26 $25.14 $22.85  
Diluted 23.25 22.07 20.94   25.01 23.93   23.73 23.66 21.57  
                 
Total Class A and Common shares outstanding (shares in thousands) 27,758 27,758 27,758   27,839 27,956   27,956 28,405 28,405  
                 

Guardian Capital Group Limited is a diversified financial services company founded in 1962. The Company provides institutional and high net worth investment management services to clients; financial services to international investors; and services to financial advisors in its national mutual fund dealer, securities dealer, and life insurance managing general agency. Its Common and Class A shares are listed on The Toronto Stock Exchange.

For further information, contact:

Donald Yi George Mavroudis
Chief Financial Officer President and Chief Executive Officer
(416) 350-3136 (416) 364-8341

(
1
) The Company’s management uses EBITDA, EBITDA per share, Adjusted cash flow from operations, Adjusted cash flow from operations per share, Shareholders’ equity per share and Securities per share to evaluate and assess the performance of its business. These measures do not have standardized measures under International Financial Reporting Standards (“IFRS”), and are therefore unlikely to be comparable to similar measures presented by other companies. However, management believes that most shareholders, creditors, other stakeholders and investment analysts prefer to include the use of these measures in analyzing the Company’s results. The Company defines EBITDA as net earnings before interest, income taxes, amortization, stock-based compensation, net gains or losses, less amounts attributable to non-controlling interests. The Company defines Adjusted cash flow from operations as net cash from operating activities, net of changes in non-cash working capital items and non-controlling interests. The most comparable IFRS measures are Net earnings, which were $42.7 million for the quarter ended September 30, 2020 (2019 – $9.0 million), and Net cash from operating activities, which was $22.4 million for the quarter ended September 30, 2020 (2019 – $22.7 million). The per share amounts for EBITDA, Adjusted cash flow from operations, Shareholders’ equity and Securities are calculated by dividing the amounts by diluted shares, which Is calculated in a manner similar to net earnings attributable to shareholders per share. More detailed descriptions of these non-IFRS measures are provided in the Company’s Management’s Discussions and Analysis, including a reconciliation of these measures to their most comparable IFRS measures.

Osmotica Pharmaceuticals plc to Present at 2020 Jefferies Virtual London Healthcare Conference

BRIDGEWATER, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) — Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the 2020 Jefferies Virtual London Healthcare Conference as follows:

Date: Wednesday, November 18, 2020
Time: 11:25 a.m. Eastern Time
Webcast: https://wsw.com/webcast/jeff141/osmt/1873875

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.osmotica.com under the “Investor & News” section.

About Osmotica
Pharmaceuticals plc

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting Upneeq. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations.

Osmotica has operations in the United States, Argentina, and Hungary.

Investor and Media Relations for Osmotica Pharmaceuticals plc

Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: [email protected] 

O-I Issues 2020 Green Bond Allocation Update

Green Bond Net Proceeds Allocated for Sustainable Projects

Perrysburg, Ohio, Nov. 12, 2020 (GLOBE NEWSWIRE) — In November of 2019, O-I European Group B.V., a subsidiary of O-I Glass, Inc. (NYSE: O-I) was the first packaging Company to issue a Green Bond (EUR 500 million). The company has committed to allocate an amount equal to the net proceeds from the Green Bond offering to finance and/or refinance new and/or existing Eligible Green Projects within 36 months from the issue date of the Green Bond.  As of November 2020, the Company has allocated EUR 255.6 million to Eligible Green Projects.

This allocation includes new investments in purchasing recycled glass (cullet) to further improve the environmental footprint of O-I’s products and production. The purchase of cullet qualifies as an Eligible Green Project as it supports the circular economy through building demand for post-consumer recycled glass and increasing recycled content in new glass packaging.

“Sustainability is integrated into every aspect of O-I’s culture and operations,” said Andres Lopez, Chief Executive Officer for O-I. “Our vision is to be the most innovative, sustainable, and chosen supplier of brand-building packaging, building value for all stakeholders. This Green Bond represents our ongoing commitment to find and execute innovative strategies to elevate our sustainability ambitions.”

To advance these aspirations and ensure sustainability initiatives are driven deep into the company, O-I also recently appointed its first Chief Sustainability Officer, Randolph Burns, who reports directly to the CEO.  The Company is actively working to improve the U.S. glass recycling system, building on the successful model in Europe where glass recycling outpaces all other packaging materials.

“We also have initiated a glass advocacy campaign initially focused in the U.S.,” Lopez continued. “This effort will ensure to rebalance the public discussion on social and traditional media with regards to the inherent sustainable nature of glass as well as emphasizing the many benefits of our product including the healthy, premium and brand building characteristics of glass.”

O-I sustainability ambitions are also aligned with the United Nations Sustainable Development Goals and include science-based targets to reduce emissions.

The investment in cullet directly supports these targets by cutting carbon emissions, reducing energy and conserving natural resources while diverting valuable glass feedstock from the landfills. For example, for every 10 percent of cullet used in production, energy consumption is reduced by three percent and carbon emissions are cut by about five percent.

The cullet purchased as a result of Green Bond net proceeds corresponds with the conservation of more than 1.4 million metric tons of CO2—or the equivalent CO2 generated to electrically power all the homes in the state of Vermont for one year.

Other sustainability initiatives the company is currently pursuing include the process of converting seven North American plants to LED lighting and the use of Oxy-Fuel to increase furnace efficiencies.

The shift to LED lighting at the Muskogee, Auburn, Windsor, Waco, Winston-Salem, Lapel and Brampton facilities reduces energy consumption associated with production—further contributing to decarbonization. The expected energy savings in Windsor, alone, is the equivalent to saving three million pounds of carbon per year—or the equivalent of removing 300 cars from the road.

To advance energy reduction, O-I is also investing in the use of oxy-fuel for furnaces, which uses purified oxygen, rather than air, during combustion. This shift reduces energy input while minimizing gas flow and emissions. Most recently, facilities in Villotta, Italy and Jarvakandi, Estonia have incorporated Oxy-Fuel, achieving the lowest CO2 intensities per ton in the O-I network. O-I’s revolutionary MAGMA technology also advances the sustainability of glass manufacturing by, among other things, increasing flexibility with on-off technology, reparability, potential co-location or near-location possibilities and light weighting.

Management’s assertion on the allocation of net proceeds to qualifying Eligible Green Projects as well as the examination report of our independent accountants are available on the O-I website, along with information on O-I’s overall sustainability agenda.

“As the leader in the glass packaging industry, we will continue to innovate and raise our sustainability ambitions,” said Burns. “We are continuously seeking new, and more sustainable, ways to improve our performance in our packaging and our operations, as well as providing our customers with premium packaging that enhances their brand, while helping to achieve their sustainability goals.”

About O-I 

At O-I Glass, Inc. (NYSE: OI), we love glass and we’re proud to make more of it than any other glass bottle or jar producer in the world. We love that it’s beautiful, pure and completely recyclable. With global headquarters in Perrysburg, Ohio, we are the preferred partner for many of the world’s leading food and beverage brands. Working hand and hand with our customers, we give our passion and expertise to make their bottles iconic and help build their brands around the world. With more than 25,500 people at 72 plants in 20 countries, O-I has a global impact, achieving revenues of $6.7 billion in 2019. For more information, visit o-i.com.  

Forward-Looking Statements

This press release contains “forward-looking” statements related to O-I Glass, Inc. (“O-I Glass” or the “company”) within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Section 27A of the Securities Act of 1933. Forward-looking statements reflect the company’s current expectations and projections about future events at the time, and thus involve uncertainty and risk. The words “believe,” “expect,” “anticipate,” “will,” “could,” “would,” “should,” “may,” “plan,” “estimate,” “intend,” “predict,” “potential,” “continue,” and the negatives of these words and other similar expressions generally identify forward-looking statements.

It is possible that the company’s future financial performance may differ from expectations due to a variety of factors including, but not limited to the following: (1) the company’s ability to obtain the benefits it anticipates from the Corporate Modernization, (2) risks inherent in, and potentially adverse developments related to, the Chapter 11 bankruptcy proceeding involving the company’s wholly owned subsidiary Paddock Enterprise, LLC (“Paddock”), that could adversely affect the company and the company’s liquidity or results of operations, including the impact of deconsolidating Paddock from the company’s financials, risks from asbestos-related claimant representatives asserting claims against the company and potential for litigation and payment demands against the company by such representatives and other third parties, (3) the amount that will be necessary to fully and finally resolve all of Paddock’s asbestos-related claims and the company’s obligations to make payments to resolve such claims under the terms of its support agreement with Paddock, (4) the company’s ability to manage its cost structure, including its success in implementing restructuring or other plans aimed at improving the company’s operating efficiency and working capital management, achieving cost savings, and remaining well-positioned to address the company’s legacy liabilities, (5) the company’s ability to acquire or divest businesses, acquire and expand plants, integrate operations of acquired businesses and achieve expected benefits from acquisitions, divestitures or expansions, (6) the company’s ability to achieve its strategic plan, (7) foreign currency fluctuations relative to the U.S. dollar, (8) changes in capital availability or cost, including interest rate fluctuations and the ability of the company to refinance debt on favorable terms, (9) the general political, economic and competitive conditions in markets and countries where the company has operations, including uncertainties related to Brexit, economic and social conditions, disruptions in the supply chain, competitive pricing pressures, inflation or deflation, changes in tax rates and laws, natural disasters, and weather,  (10) the impact of COVID-19 and the various governmental, industry and consumer actions related thereto, (11) the company’s ability to generate sufficient future cash flows to ensure the company’s goodwill is not impaired, (12) consumer preferences for alternative forms of packaging, (13) cost and availability of raw materials, labor, energy and transportation, (14) consolidation among competitors and customers, (15) unanticipated expenditures with respect to data privacy, environmental, safety and health laws, (16) unanticipated operational disruptions, including higher capital spending, (17) the company’s ability to further develop its sales, marketing and product development capabilities, (18) the failure of the company’s joint venture partners to meet their obligations or commit additional capital to the joint venture, (19) the ability of the company and the third parties on which it relies for information technology system support to prevent and detect security breaches related to cybersecurity and data privacy, (20) changes in U.S. trade policies, and the other risk factors discussed in the company’s Annual Report on Form 10-K for the year ended December 31, 2019, Quarterly Report on form 10-Q for the quarterly period ended September 30, 2020 and any subsequently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q or the company’s other filings with the Securities and Exchange Commission.

It is not possible to foresee or identify all such factors.  Any forward-looking statements in this document are based on certain assumptions and analyses made by the company in light of its experience and perception of historical trends, current conditions, expected future developments, and other factors it believes are appropriate in the circumstances.  Forward-looking statements are not a guarantee of future performance and actual results or developments may differ materially from expectations.  While the company continually reviews trends and uncertainties affecting the company’s results or operations and financial condition, the company does not assume any obligation to update or supplement any particular forward-looking statements contained in this document.

Jim Woods
PR Lead, Americas North
[email protected]

Cancer Genetics Reports Third Quarter 2020 Financial Results

RUTHERFORD, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced today financial and operating results for the quarter ended September 30, 2020.

RECENT STRATEGIC AND OPERATIONAL HIGHLIGHTS

  Entered into a definitive agreement to merge with StemoniX, a leader in powering the discovery of new medicines through the convergence of novel human biology and software technologies
     
  Continued stability and customer loyalty from biopharma partners in vivoPharm’s drug discovery business
     
  Commenced a joint proof-of-concept program with StemoniX to confirm a best-in-class drug discovery platform converging in-vivo, in-vitro and in-silico innovations
     
  Closed on $3 million of financing in October 2020 to meet cash requirements pending the proposed upcoming merger with StemoniX

John A. Roberts, Chief Executive Officer of Cancer Genetics stated, “During Q3 2020, we continued to make advances to enhance value for our shareholders and customers. The key event of the quarter was signing a definitive agreement to merge with StemoniX. Based on our lengthy search for a merger partner since last year, StemoniX proved to be the most attractive opportunity for our shareholders by extracting meaningful value from synergies with our vivoPharm drug discovery business and the continued transformation of our business model.”

Mr. Roberts continued, “To illustrate the relationship more fully, we have announced a joint proof-of-concept program between StemoniX and vivoPharm®, a subsidiary of Cancer Genetics. The initial program will assess CNS (central nervous system) safety and toxicity of novel compounds, and will set the stage for future partnership collaborations with drug developers. We are also exceptionally encouraged with their recent announcement related to the publication of a new research paper, “Screening for modulators of neural network activity in 3D human iPSC-derived cortical spheroids,” in the journal PLOS ONE. The research describes how the StemoniX microBrain 3D platform can be used in functional high-throughput screens to identify potentially new therapeutics for central nervous system (CNS) indications, further supporting our belief in the increasing value this merger will bring to our combined shareholders.”

Cancer Genetics continued to service customers through the company’s Discovery Services business, vivoPharm. We experienced a delay in new contract signings in Q3 while many of our customers diverted their resources to COVID-19 initiatives and oriented their scientific and discovery teams to remote working environments.

The Company filed its quarterly report for Q3 2020 on Form 10-Q today with the Securities and Exchange Commission.

THIRD QUARTER 2020 FINANCIAL RESULTS

The Company reported total revenue from continuing operations of $1.6 million for the third quarter of 2020 compared to revenue of $2.1 million in the third quarter of 2019, a decrease of approximately $0.5 million or 24% principally due to delays in drug discovery programs impacting our customer’s preclinical projects teams as customers diverted their resources to COVID-19 initiatives and oriented their scientific and discovery teams to remote working environments.

Gross profit margin in the third quarter 2020 was 41.8% or $0.7 million as compared to gross profit margin from continuing operations of 52.0% or $1.1 million in the third quarter of 2019. The Discovery Services business unit gross margin decreased in the third quarter of 2020 compared to 2019 principally due to the change in revenue in the comparable periods.

Total operating expenses for the third quarter of 2020 were approximately $2.0 million (including approximately $0.5 million of one-time non-recurring expenses related to merger and financing costs). This represents a decrease of 57.0% compared to total operating expenses from continuing operations for the third quarter of 2019 which were approximately $4.7 million. The decrease in total operating expenses was due to a $2.9 million goodwill impairment charge recorded in the third quarter of 2019.

Net loss from continuing operations was $1.4 million or ($0.58) per share for the third quarter of 2020. Net Loss from continuing operations was $4.8 million in the third quarter of 2019 or ($2.38) per share.

Cash and cash equivalents totaled approximately $1.1 million as of September 30, 2020.

ABOUT CANCER GENETICS

Through its vivoPharm subsidiary, the Cancer Genetics offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages, valued by the pharmaceutical industry, biotechnology companies and academic research centers. The Company is focused on precision and translational medicine to drive drug discovery and novel therapies. vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings. vivoPharm operates in The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities. For more information, please visit www.cancergenetics.com.

For more information, please visit or follow CGI at:

Internet:

www.cancergenetics.com

Twitter: @Cancer_Genetics

Additional Information about the Proposed Merger and Where to Find It

In connection with the proposed merger between CGI and StemoniX, Inc. (“StemoniX”), CGI has filed relevant materials with the Securities and Exchange Commission (the “SEC”), including a registration statement on Form S-4 that contains a proxy statement/prospectus/information statement. INVESTORS AND SECURITY HOLDERS OF CGI AND STEMONIX ARE URGED TO READ THESE MATERIALS (AS WELL AS AMENDMENTS AND SUPPLEMENTS THERETO AND ANY DOCUMENTS INCORPORATED BY REFERENCE THEREIN) WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT CGI, STEMONIX AND THE PROPOSED MERGER. The proxy statement/prospectus/information statement and other relevant materials (when they become available), and any other documents filed by CGI with the SEC, may be obtained free of charge at the SEC website at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by CGI by directing a written request to: Cancer Genetics, Inc., c/o John A. Roberts, Chief Executive Officer, 201 Route 17 North 2nd Floor, Rutherford, NJ 07070. Investors and security holders are urged to read the Registration Statement and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed merger.

This report shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities in connection with the proposed merger shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Participants in the Solicitation

CGI and its directors and executive officers and StemoniX and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of CGI in connection with the proposed transaction under the rules of the SEC. Information about the directors and executive officers of CGI and their ownership of shares of CGI’s common stock is set forth in its Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the SEC on May 29, 2020, and in subsequent documents filed and to be filed with the SEC, including the Registration Statement referred to above. Additional information regarding the persons who may be deemed participants in the proxy solicitations and a description of their direct and indirect interests in the proposed merger, by security holdings or otherwise, are included in the Registration Statement and other relevant materials to be filed with the SEC when they become available. These documents are available free of charge at the SEC web site (www.sec.gov) and from the Chief Executive Officer at CGI at the address described above.

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Cancer Genetics, Inc.’s expectations regarding future financial and/or operating results, the proposed merger with StemoniX, Inc., the potential for our tests and services and future revenues or growth in this press release constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our ability to satisfy all closing conditions to the merger with StemoniX, Inc. and realize the expected benefits therefrom, our attempts to adapt to the global coronavirus pandemic, our attempts to achieve profitability by increasing sales of our pre-clinical services, maintain our existing customer base and avoid cancellation of customer contracts or discontinuance of trials, our attempts to raise capital to meet our liquidity needs, market and other conditions, and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2019 and Form 10-Q for the quarter ended June 30, 2020, along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

Investor Contacts:

Jennifer K. Zimmons. Ph.D.
Investor Relations
Zimmons International Communications, Inc
Email: [email protected]
Phone: +1.917.214.3514

Cancer Genetics, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets (Unaudited)

(in thousands, except par value)

    September 30,     December 31,  
    2020     2019  
ASSETS                
CURRENT ASSETS                
Cash and cash equivalents   $ 1,133     $ 3,880  
Restricted cash           350  
Accounts receivable     773       696  
Earn-Out from siParadigm, net, current portion     141       747  
Excess Consideration Note           888  
Other current assets     754       546  
Current assets of discontinuing operations           71  
Total current assets     2,801       7,178  
FIXED ASSETS, net of accumulated depreciation     488       558  
OTHER ASSETS                
Operating lease right-of-use assets, net of accumulated amortization     47       94  
Earn-Out from siParadigm, less current portion           356  
Patents and other intangible assets, net of accumulated amortization     2,563       2,895  
Investment in joint venture     56       92  
Goodwill     3,090       3,090  
Other     645       641  
Total other assets     6,401       7,168  
Total Assets   $ 9,690     $ 14,904  
LIABILITIES AND STOCKHOLDERS’ EQUITY                
CURRENT LIABILITIES                
Accounts payable and accrued expenses   $ 2,863     $ 2,072  
Obligations under operating leases, current portion     38       193  
Obligations under finance leases, current portion     53       68  
Deferred revenue     798       1,217  
Note payable, net           1,277  
Advance from NovellusDx, Ltd., net           350  
Advance from siParadigm, current portion           566  
Due to Interpace Biosciences, Inc.     421        
Current liabilities of discontinuing operations     578       1,229  
Total current liabilities     4,751       6,972  
Obligations under operating leases, less current portion     10       10  
Obligation under finance leases, less current portion     79       107  
Advance from siParadigm, less current portion           252  
Warrant liability     45       178  
Total Liabilities     4,885       7,519  
STOCKHOLDERS’ EQUITY                
Preferred stock, authorized 9,764 shares, $0.0001 par value, none issued            
Common stock, authorized 100,000 shares, $0.0001 par value, 2,506 and 2,104 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively            
Additional paid-in capital     173,517       171,783  
Accumulated other comprehensive income (loss)     (56 )     26  
Accumulated deficit     (168,656 )     (164,424 )
Total Stockholders’ Equity     4,805       7,385  
Total Liabilities and Stockholders’ Equity   $ 9,690     $ 14,904  

Cancer Genetics, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited)

(in thousands, except per share amounts)

    Three Months Ended September 30,     Nine Months Ended September 30,  
    2020     2019     2020     2019  
Revenue   $ 1,568     $ 2,069     $ 4,440     $ 5,416  
Cost of revenues     912       993       2,366       2,729  
Gross profit     656       1,076       2,074       2,687  
Operating expenses:                                
General and administrative     1,217       1,239       4,982       4,205  
Sales and marketing     354       322       979       824  
Impairment of goodwill           2,873             2,873  
Merger costs     454       284       454       284  
Total operating expenses     2,025       4,718       6,415       8,186  
Loss from operations     (1,369 )     (3,642 )     (4,341 )     (5,499 )
Other income (expense):                                
Interest expense     (108 )     (200 )     (283 )     (1,327 )
Interest income                 4        
Change in fair value of acquisition note payable           5       4       12  
Change in fair value of other derivatives                       86  
Change in fair value of warrant liability     (19 )     34       133       233  
Change in fair value of siParadigm Earn-Out     (1 )     (982 )     (66 )     (982 )
Other income (expense)     146             251       (11 )
Total other income (expense)     18       (1,143 )     43       (1,989 )
Loss from continuing operations before income taxes     (1,351 )     (4,785 )     (4,298 )     (7,488 )
Income tax expense (benefit)     2             8       (512 )
Loss from continuing operations     (1,353 )     (4,785 )     (4,306 )     (6,976 )
Income from discontinuing operations           6,760       74       561  
Net income (loss)     (1,353 )     1,975       (4,232 )     (6,415 )
Foreign currency translation gain (loss)     (29 )     (120 )     (82 )     (161 )
Comprehensive income (loss)   $ (1,382 )   $ 1,855     $ (4,314 )   $ (6,576 )
                                 
Basic and diluted net loss per share from continuing operations   $ (0.58 )   $ (2.38 )   $ (1.96 )   $ (3.77 )
Basic and diluted net income per share from discontinuing operations           3.36       0.03       0.30  
Basic and diluted net income (loss) per share   $ (0.58 )   $ 0.98     $ (1.93 )   $ (3.47 )
                                 
Basic and diluted weighted-average shares outstanding     2,328       2,014       2,193       1,850  

Cancer Genetics, Inc. and Subsidiaries

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited)

(in thousands)

    Three and Nine Months Ended September 30, 2020  
                Additional     Accumulated Other              
    Common Stock     Paid-in     Comprehensive     Accumulated        
    Shares     Amount     Capital     Income (Loss)     Deficit     Total  
Balance, January 1, 2020     2,104     $     $ 171,783     $ 26     $ (164,424 )   $ 7,385  
Stock based compensation—employees                 58                   58  
Issuance of common stock—VenturEast settlement     3             12                   12  
Unrealized gain on foreign currency translation                       104             104  
Net loss                             (1,179 )     (1,179 )
Balance, March 31, 2020     2,107             171,853       130       (165,603 )     6,380  
Stock based compensation—employees                 47                   47  
Fair value of common stock exchanged to settle Note Payable     153             531                   531  
Unrealized loss on foreign currency translation                       (157 )           (157 )
Net loss                             (1,700 )     (1,700 )
Balance, June 30, 2020     2,260             172,431       (27 )     (167,303 )     5,101  
Stock based compensation—employees                 39                   39  
Fair value of common stock exchanged to settle Note Payable     246             1,047                   1,047  
Unrealized loss on foreign currency translation                       (29 )           (29 )
Net loss                             (1,353 )     (1,353 )
Balance, September 30, 2020     2,506     $     $ 173,517     $ (56 )   $ (168,656 )   $ 4,805  
       
     Three and Nine Months Ended September 30, 2019  
                Additional     Accumulated Other              
    Common Stock     Paid-in     Comprehensive     Accumulated        
    Shares     Amount     Capital     Income (Loss)     Deficit     Total  
Balance, January 1, 2019     924     $     $ 164,458     $ 60     $ (157,716 )   $ 6,802  
Stock based compensation—employees                 158                   158  
Issuance of common stock – 2019 Offerings, net     952             5,412                   5,412  
Unrealized loss on foreign currency translation                       (76 )           (76 )
Net loss                             (4,617 )     (4,617 )
Balance, March 31, 2019     1,876             170,028       (16 )     (162,333 )     7,679  
Stock based compensation—employees                 102                   102  
Issuance of common stock – Iliad conversions     51             350                   350  
Increase in fair value of embedded conversion option                 547                   547  
Unrealized gain on foreign currency translation                       35             35  
Net loss                             (3,773 )     (3,773 )
Balance, June 30, 2019     1,927             171,027       19       (166,106 )     4,940  
Stock based compensation—employees                 57                   57  
Issuance of common stock – Iliad exchanges     174             612                   612  
Unrealized gain on foreign currency translation                       (120 )           (120 )
Net loss                             1,975       1,975  
Balance, September 30, 2019     2,101     $     $ 171,696     $ (101 )   $ (164,131 )   $ 7,464  

Cancer Genetics, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows (Unaudited)

(in thousands)

    Nine Months Ended September 30,  
    2020     2019  
CASH FLOWS FROM OPERATING ACTIVITIES                
Net loss   $ (4,232 )   $ (6,415 )
Income from discontinuing operations     (74 )     (561 )
Net loss from continuing operations     (4,306 )     (6,976 )
                 
Adjustments to reconcile net loss to net cash used in operating activities, continuing operations:                
Depreciation     130       53  
Amortization     332       328  
Stock-based compensation     152       226  
Impairment of goodwill           2,873  
Change in fair value of warrant liability, acquisition note payable and other derivatives     (137 )     (331 )
Amortization of operating lease right-of-use assets     154       123  
Change in fair value of siParadigm Earn-Out     66       982  
Amortization of discount on debt and debt issuance costs     71       470  
Loss on extinguishment of debt     120       256  
Interest added to Convertible Note           268  
Changes in:                
Accounts receivable     (72 )     (36 )
Other current assets     (203 )     (422 )
Other non-current assets     (3 )     (2 )
Accounts payable, accrued expenses and deferred revenue     400       1,516  
Due to Interpace Biosciences, Inc.     421        
Obligations under operating leases     (183 )     (156 )
Net cash used in operating activities, continuing operations     (3,058 )     (828 )
Net cash used in operating activities, discontinuing operations     (514 )     (5,309 )
Net cash used in operating activities     (3,572 )     (6,137 )
CASH FLOWS FROM INVESTING ACTIVITIES                
Purchase of fixed assets     (39 )     (21 )
Distribution from Joint Venture     36        
Receipts from Excess Consideration Note     888        
Net cash received in disposal of Clinical Business     885       (21 )
Net cash received in disposal of BioPharma Business     78       3,044  
Net cash provided by (used in) investing activities, continuing operations     963       3,023  
Net cash provided by investing activities, discontinuing operations                
Net cash provided by investing activities     (66 )     (36 )
CASH FLOWS FROM FINANCING ACTIVITIES           5,412  
Principal payments on obligations under finance leases     (350 )      
Proceeds from offerings of common stock, net of certain offering costs     (416 )     5,376  
Payments on Advance from NovellusDx, Ltd.           (115 )
Net cash provided by (used in) financing activities, continuing operations     (416 )     5,261  
Net cash used in financing activities, discontinuing operations     (72 )     (161 )
Net cash provided by (used in) financing activities     (3,097 )     1,986  
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH                
Beginning     4,230       511  
Ending   $ 1,133     $ 2,497  
                 
RECONCILIATION OF CASH AND CASH EQUIVALENTS AND RESTRICTED                
CASH TO THE CONSOLIDATED BALANCE SHEETS:                
Cash and cash equivalents   $ 1,133     $ 2,147  
Restricted cash           350  
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH   $ 1,133     $ 2,497  
                 
SUPPLEMENTAL CASH FLOW DISCLOSURE                
Cash paid for interest   $ 11     $ 1,185  
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES                
Common stock issued in VentureEast settlement   $ 12     $  
Fair value of common stock exchanged to settle Note Payable     1,578        
Right of use assets obtained through operating leases     27        
Fixed assets obtained through finance leases     17       145  
Conversion of debt and accrued interest into common stock           350  
Increase in fair value of conversion option             547  
Exchanges of principal on Convertible Note for common stock             612  
Disposal of Clinical Business:                
Goodwill   $     $ 1,188  
Accounts payable and accrued expenses           (287 )
Gain on disposal of Clinical Business           1,222  
Earn-Out from siParadigm           (2,269 )
Advance from siParadigm, net of repayments           974  
Net cash received in disposal of Clinical Business   $     $ 828  
Disposal of BioPharma Business:                
Accounts receivable   $     $ 4,145  
Other current assets           1,142  
Fixed assets           2,998  
Operating lease right-of-use assets           1,969  
Patents and other intangible assets           42  
Goodwill           10,106  
Accounts payable and accrued expenses           (6,351 )
Obligations under operating leases           (2,110 )
Obligations under finance leases           (451 )
Deferred revenue           (1,046 )
Line of credit           (2,665 )
Term note           (6,000 )
Gain on disposal of BioPharma Business           7,274  
Note receivable from IDXG           (6,795 )
Net cash received in disposal of BioPharma Business   $     $ 2,258  

Ballantyne Strong Reports Third Quarter 2020 Operating Results

Charlotte, NC, Nov. 12, 2020 (GLOBE NEWSWIRE) —
Ballantyne Strong, Inc. (NYSE American: BTN) (the “Company”) today announced financial results for the third quarter and nine months ended September 30, 2020.


Financial and Operational Highlights

          ●     Convergent profitability improved with continued growth in recurring revenue

                        ○     Year-over-year segment gross margins increased to 47.9% from 32.4%, segment operating income improved by 169% and segment Adjusted EBITDA grew 88% to $1.7 million

          ●     Strong Entertainment began to see meaningful signs of recovery as cinema exhibitors and other entertainment operators began reopening worldwide

                        ○     Revenue decreased year over year due to COVID-19 impact on cinema operators
                                 
                        ○     Sequential revenue grew 113% from the second quarter 2020 to the third quarter as exhibitors resumed operations
                                 
                        ○     Settled business interruption claim, resulting in a gain of $2.7 million
                                 
                        ○     Signed multi-year exclusive agreements with Cinemark and Marcus Theatres

          ●     Completed sale of Strong Outdoor in early August

                        ○     Investment in Firefly increased to $13 million
                                 
                        ○     $5.3 million primarily non-cash gain recognized upon divestiture

          ●     Cash flows from operating activities from continuing operations for the first nine months of 2020 improved to $8.2 million from negative $1.0 million the same period in the prior year

“This was a busy quarter for Ballantyne Strong,” commented Mark Roberson, Chief Executive Officer. “We continued to grow our recurring revenue and profitability at Convergent; began to see a strengthening recovery in Strong Entertainment as operators began reopening worldwide; and we completed the sale of Strong Outdoor, exiting the outdoor advertising business.

“The sale of Strong Outdoor was a significant transaction providing us the flexibility to more fully participate in the upside potential of the Firefly business. We now hold a $13 million investment stake in Firefly and are one of their largest shareholders behind Google Ventures and NFX.

“Our continuing businesses, Convergent and Strong Entertainment, both gained momentum as we progressed through the quarter, and we’re excited to continue building on this progress. Convergent posted a 169% increase in operating profit as compared to the prior year as a result of the growth in DSAAS. While Strong Entertainment was down compared with the prior year due to the impact of COVID-19, we achieved substantial sequential growth compared to the second quarter of 2020. It is encouraging to see customer orders and overall business levels strengthening since operators began reopening their facilities in August. We expect those trends to continue as we progress through the fourth quarter and look ahead to 2021. Furthermore, Strong Entertainment has recently signed new partnerships with leading cinema operators, enhancing our leading position in the industry. We entered a multi-year nationwide managed services agreement with Marcus Theatres, the fourth largest cinema operator in the United States, and in October we signed a five-year exclusive worldwide screen supply agreement with Cinemark Theatres, the third largest exhibitor in the United States.”


Third Quarter 2020 Financial Review – (comparison of continuing operations to prior year quarter)

  Revenue decreased 36.3% to $9.9 million from $15.6 million. The decrease was primarily due to the impact of COVID-19 on customer demand for screen products and technical services at Strong Entertainment. At Convergent, growth in services revenue was offset by the effect of large non-recurring installation projects in the prior year period.
     
  Gross profit decreased 37.6% to $3.2 million from $5.2 million for the quarter and gross profit margins decreased to 32.8% as compared to 33.4%. Gross profit decreased as cost reduction actions and the expansion of margins at Convergent were offset by the impact of COVID-19 on business at Strong Entertainment.
     
  Net income from continuing operations was $1.0 million, or $0.07 per basic and diluted share, in the third quarter of 2020, compared to a net loss from continuing operations of $1.7 million, or ($0.11) per basic and diluted share, in the third quarter of 2019. Net income includes a gain of $2.7 million from the settlement of the business interruption insurance claim in the third quarter of 2020.
     
  Adjusted EBITDA was $0.8 million compared to $1.3 million in the prior year. Growth in Adjusted EBITDA at Convergent and reductions in corporate overhead were offset by lower contribution from Strong Entertainment due to COVID-19.


Conference Call

A conference call to discuss the 2020 third-quarter financial results will be held on Thursday, November 12, 2020 at 5:00 pm Eastern Time. Investors and analysts are invited to access the conference call by dialing 855-327-6837 (domestic) or 631-891-4304 (international) and providing the operator with conference ID number: 10011742. Please dial in at least five minutes before the start of the call to register. A replay will be available approximately three hours after the conclusion of the conference call until Saturday, December 12, 2020 by dialing 844-512-2921 in the U.S. and Canada and 412-317-6671 internationally and entering the conference ID number: 10011742.

The Company’s financial results and an accompanying slide presentation will also be available on the Investor Relations page of the Company’s website at ballantynestrong.com/investors.


Use of Non-GAAP Measures

Ballantyne Strong, Inc. prepares its consolidated financial statements in accordance with United States generally accepted accounting principles (“GAAP”). In addition to disclosing financial results prepared in accordance with GAAP, the Company discloses information regarding Adjusted EBITDA, which differs from the term EBITDA as it is commonly used. In addition to adjusting net income (loss) to exclude income taxes, interest, and depreciation and amortization, Adjusted EBITDA also excludes discontinued operations, share-based compensation, impairment charges, equity method income (loss), fair value adjustments, severance, foreign currency transaction gains (losses), transactional expenses and other cash and non-cash charges and gains.

EBITDA and Adjusted EBITDA are not measures of performance defined in accordance with GAAP. However, Adjusted EBITDA is used internally in planning and evaluating the Company’s operating performance. Accordingly, management believes that disclosure of these metrics offers investors, bankers and other stakeholders an additional view of the Company’s operations that, when coupled with the GAAP results, provides a more complete understanding of the Company’s financial results.

EBITDA and Adjusted EBITDA should not be considered as an alternative to net loss or to net cash used in operating activities as measures of operating results or liquidity. Our calculation of EBITDA and Adjusted EBITDA may not be comparable to similarly titled measures used by other companies, and the measures exclude financial information that some may consider important in evaluating the Company’s performance. A reconciliation of GAAP net loss to EBITDA and Adjusted EBITDA is included in the accompanying financial schedules.

EBITDA and Adjusted EBITDA have limitations as analytical tools, and you should not consider them in isolation, or as substitutes for analysis of our results as reported under GAAP. Some of these limitations are (i) they do not reflect our cash expenditures, or future requirements for capital expenditures or contractual commitments, (ii) they do not reflect changes in, or cash requirements for, our working capital needs, (iii) EBITDA and Adjusted EBITDA do not reflect interest expense, or the cash requirements necessary to service interest or principal payments, on our debt, (iv) although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and EBITDA and Adjusted EBITDA do not reflect any cash requirements for such replacements, (v) they do not adjust for all non-cash income or expense items that are reflected in our statements of cash flows, (vi) they do not reflect the impact of earnings or charges resulting from matters we consider not to be indicative of our ongoing operations, and (vii) other companies in our industry may calculate these measures differently than we do, limiting their usefulness as comparative measures.

We believe EBITDA and Adjusted EBITDA facilitate operating performance comparisons from period to period by isolating the effects of some items that vary from period to period without any correlation to core operating performance or that vary widely among similar companies. These potential differences may be caused by variations in capital structures (affecting interest expense), tax positions (such as the impact on periods or companies of changes in effective tax rates or net operating losses) and the age and book depreciation of facilities and equipment (affecting relative depreciation expense). We also present EBITDA and Adjusted EBITDA because (i) we believe these measures are frequently used by securities analysts, investors and other interested parties to evaluate companies in our industry, (ii) we believe investors will find these measures useful in assessing our ability to service or incur indebtedness, and (iii) we use EBITDA and Adjusted EBITDA internally as benchmarks to evaluate our operating performance or compare our performance to that of our competitors.

For further information, please refer to Ballantyne Strong, Inc.’s Quarterly Report on Form 10-Q to be filed with the Securities and Exchange Commission on or about November 12, 2020, available online at www.sec.gov.


About Ballantyne Strong, Inc.

Ballantyne Strong (www.ballantynestrong.com) and its subsidiaries engage in diverse business activities including the design, integration and installation of technology solutions for a broad range of applications; development and delivery of out-of-home messaging, advertising and communications; manufacturing of projection screens; and providing managed services including monitoring of networked equipment. The Company focuses on serving the entertainment and retail markets.


Forward-Looking Statements

Except for the historical information in this press release, it includes forward-looking statements which involve a number of risks and uncertainties, including but not limited to those discussed in the “Risk Factors” section contained in Item 1A in our Annual Report on Form 10-K for the year ended December 31, 2019, Part II, Item 1A of the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 and the Company’s subsequent filings with the SEC, and the following risks and uncertainties: the negative impact that the COVID-19 pandemic has already had, and may continue to have, on the Company’s business and financial condition, the Company’s ability to maintain and expand its revenue streams to compensate for the lower demand for the Company’s digital cinema products and installation services, potential interruptions of supplier relationships or higher prices charged by suppliers, the Company’s ability to successfully compete and introduce enhancements and new features that achieve market acceptance and that keep pace with technological developments, the Company’s ability to successfully execute its capital allocation strategy, the Company’s ability to maintain its brand and reputation and retain or replace its significant customers, challenges associated with the Company’s long sales cycles, the impact of a challenging global economic environment or a downturn in the markets (such as the current economic disruption and market volatility generated by the ongoing COVID-19 pandemic), economic and political risks of selling products in foreign countries (including tariffs), risks of non-compliance with U.S. and foreign laws and regulations, potential sales tax collections and claims for uncollected amounts, cybersecurity risks and risks of damage and interruptions of information technology systems, the Company’s ability to retain key members of management and successfully integrate new executives, the Company’s ability to complete acquisitions, strategic investments, entry into new lines of business, divestitures, mergers or other transactions on acceptable terms or at all, the Company’s ability to utilize or assert its intellectual property rights, the impact of natural disasters and other catastrophic events (such as the ongoing COVID-19 pandemic), the adequacy of insurance, the impact of having a controlling stockholder and vulnerability to fluctuation in the Company’s stock price. Given the risks and uncertainties, readers should not place undue reliance on any forward-looking statement and should recognize that the statements are predictions of future results which may not occur as anticipated. Many of the risks listed above have been, and may further be, exacerbated by the COVID-19 pandemic, its impact on the cinema and entertainment industry, and the worsening economic environment. Actual results could differ materially from those anticipated in the forward-looking statements and from historical results, due to the risks and uncertainties described herein, as well as others not now anticipated. New risk factors emerge from time to time and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Except where required by law, the Company assumes no obligation to update, withdraw or revise any forward-looking statements to reflect actual results or changes in factors or assumptions affecting such forward-looking statements.


For Investor Relations Inquiries:

Mark Roberson John Nesbett / Jennifer Belodeau
Ballantyne Strong, Inc. – Chief Executive Officer IMS Investor Relations
704-994-8279 203-972-9200

[email protected]

[email protected]

Ballantyne Strong, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(In thousands, except par values)

    September 30, 2020     December 31, 2019  
    (unaudited)        
Assets                
Current assets:                
Cash and cash equivalents   $ 7,026     $ 4,951  
Restricted cash     352       351  
Accounts receivable (net of allowance for doubtful accounts of $783 and $1,291, respectively)     6,115       12,898  
Inventories, net     2,816       2,879  
Current assets of discontinued operations           320  
Other current assets     1,735       1,624  
Total current assets     18,044       23,023  
Property, plant and equipment (net of accumulated depreciation of $11,363 and $10,030, respectively)     9,028       10,069  
Operating lease right-of-use assets     4,705       5,581  
Finance lease right-of-use assets     2,465       2,563  
Investments     22,006       13,311  
Intangible assets, net     1,214       1,534  
Goodwill     895       919  
Long-term assets of discontinued operations           585  
Other assets     31       48  
Total assets   $ 58,388     $ 57,633  
                 
Liabilities and Stockholders’ Equity                
Current liabilities:                
Accounts payable   $ 3,448     $ 2,969  
Accrued expenses     3,464       4,416  
Short-term debt     2,972       3,080  
Current portion of long-term debt     1,055       998  
Current portion of operating lease obligations     743       846  
Current portion of finance lease obligations     1,820       1,586  
Deferred revenue and customer deposits     4,198       2,706  
Current liabilities of discontinued operations           704  
Total current liabilities     17,700       17,305  
Long-term debt, net of current portion and debt issuance costs     2,617       3,019  
Operating lease obligations, net of current portion     4,107       4,662  
Finance lease obligations, net of current portion     3,111       3,988  
Deferred income taxes     3,053       2,649  
Long-term liabilities of discontinued operations           147  
Other long-term liabilities     120       154  
Total liabilities     30,708       31,924  
Commitments, contingencies and concentrations                
                 
Stockholders’ equity:                
Preferred stock, par value $.01 per share; authorized 1,000 shares, none outstanding            
Common stock, par value $.01 per share; authorized 25,000 shares; issued 17,584 and 17,410 shares at September 30, 2020 and December 31, 2019, respectively; outstanding 14,790 and 14,616 shares at September 30, 2020 and December 31, 2019, respectively     176       174  
Additional paid-in capital     43,311       42,589  
Retained earnings     7,472       6,001  
Less 2,794 of common shares in treasury, at cost     (18,586 )     (18,586 )
Accumulated other comprehensive loss     (4,693 )     (4,469 )
Total stockholders’ equity     27,680       25,709  
Total liabilities and stockholders’ equity   $ 58,388     $ 57,633  

Ballantyne Strong, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

(Unaudited)

    Three Months Ended September 30,     Nine Months Ended

September 30,
 
    2020     2019     2020     2019  
Net product sales   $ 4,460     $ 9,192     $ 13,095     $ 20,840  
Net service revenues     5,447       6,358       15,393       21,057  
Total net revenues     9,907       15,550       28,488       41,897  
Cost of products sold     3,564       5,603       10,119       17,526  
Cost of services     3,096       4,746       9,520       11,435  
Total cost of revenues     6,660       10,349       19,639       28,961  
Gross profit     3,247       5,201       8,849       12,936  
Selling and administrative expenses:                                
Selling     678       956       2,234       2,986  
Administrative     2,914       4,055       10,119       11,709  
Total selling and administrative expenses     3,592       5,011       12,353       14,695  
Loss on disposal of assets     (18 )     (3 )     (18 )     (67 )
(Loss) income from operations     (363 )     187       (3,522 )     (1,826 )
Other income (expense):                                
Interest income           1             3  
Interest expense     (254 )     (263 )     (794 )     (568 )
Fair value adjustment to notes receivable           (845 )           (2,153 )
Foreign currency transaction (loss) gain     (173 )     66       12       (154 )
Other income, net     2,749       416       2,873       650  
Total other income (expense)     2,322       (625 )     2,091       (2,222 )
Income (loss) from continuing operations before income taxes and equity method investment loss     1,959       (438 )     (1,431 )     (4,048 )
Income tax expense     (526 )     (731 )     (1,022 )     (1,295 )
Equity method investment loss     (460 )     (496 )     (580 )     (1,223 )
Net income (loss) from continuing operations     973       (1,665 )     (3,033 )     (6,566 )
Net income (loss) from discontinued operations     4,673       (123 )     4,504       (2,790 )
Net income (loss)   $ 5,646     $ (1,788 )   $ 1,471     $ (9,356 )
                                 
Basic net income (loss) per share                                
Continuing operations   $ 0.07     $ (0.11 )   $ (0.21 )   $ (0.46 )
Discontinued operations     0.31       (0.01 )     0.31       (0.19 )
Basic net income (loss) per share   $ 0.38     $ (0.12 )   $ 0.10     $ (0.65 )
                                 
Diluted net income (loss) per share                                
Continuing operations   $ 0.07     $ (0.11 )   $ (0.21 )   $ (0.46 )
Discontinued operations     0.31       (0.01 )     0.31       (0.19 )
Diluted net income (loss) per share   $ 0.38     $ (0.12 )   $ 0.10     $ (0.65 )

Ballantyne Strong, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

    Nine Months Ended September 30,  
    2020     2019  
Cash flows from operating activities:                
Net loss from continuing operations   $ (3,033 )   $ (6,566 )
Adjustments to reconcile net loss from continuing operations to net cash provided by (used in) operating activities:                
Provision for (recovery of) doubtful accounts     397       (509 )
Provision for obsolete inventory     41       245  
Provision for warranty     14       24  
Depreciation and amortization     2,634       2,214  
Amortization and accretion of operating leases     814       788  
Fair value adjustment to notes receivable           2,153  
Equity method investment loss     580       1,223  
Loss on disposal of assets           67  
Gain on business interruption claim settlement     (789 )      
Gain on Firefly transaction (Note 3)            
Deferred income taxes     72       (129 )
Stock-based compensation expense     724       798  
Changes in operating assets and liabilities:                
Accounts receivable     4,793       776  
Inventories     (28 )     (96 )
Current income taxes     269       229  
Other assets     35       (130 )
Accounts payable and accrued expenses     1,024       (2,000 )
Deferred revenue and customer deposits     1,469       797  
Operating lease obligations     (857 )     (875 )
Net cash provided by (used in) operating activities from continuing operations     8,159       (991 )
Net cash provided by operating activities from discontinued operations     598       1,407  
Net cash provided by operating activities     8,757       416  
                 
Cash flows from investing activities:                
Proceeds from sale of property, plant and equipment   $     $ 121  
Investment in Firefly Systems, Inc.     (4,000 )      
Capital expenditures     (729 )     (1,717 )
Net cash used in investing activities from continuing operations     (4,729 )     (1,596 )
                 
Cash flows from financing activities:                
Proceeds from issuance of long-term debt           237  
Principal payments on short-term debt     (450 )     (323 )
Principal payments on long-term debt     (427 )     (725 )
Proceeds from borrowing under credit facility     5,040        
Repayments of borrowings under credit facility     (5,040 )      
Proceeds from Paycheck Protection Program Loan     3,174        
Repayment of Paycheck Protection Program Loan     (3,174 )      
Payments on capital lease obligations     (1,195 )     (420 )
Net cash used in financing activities from continuing operations     (2,072 )     (1,231 )
Effect of exchange rate changes on cash and cash equivalents     120       46  
Net increase (decrease) in cash and cash equivalents and restricted cash from continuing operations     1,478       (3,772 )
Net increase in cash and cash equivalents and restricted cash from discontinued operations     598       1,407  
Net increase (decrease) in cash and cash equivalents and restricted cash     2,076       (2,365 )
Cash and cash equivalents and restricted cash at beginning of period     5,302       7,048  
Cash and cash equivalents and restricted cash at end of period   $ 7,378     $ 4,683  

Ballantyne Strong, Inc. and Subsidiaries

Summary by Business Segments

(In thousands)

(Unaudited)

    Three Months Ended September 30,     Nine Months Ended September 30,  
    2020     2019     2020     2019  
                         
Strong Entertainment                                
Revenue   $ 5,260     $ 10,928     $ 15,041     $ 26,405  
Gross profit     889       3,669       2,769       8,621  
Operating (loss) income     (79 )     2,230       (894 )     4,646  
Adjusted EBITDA     133       2,444       (137 )     5,367  
                                 
Convergent                                
Revenue   $ 4,346     $ 4,532     $ 12,954     $ 15,204  
Gross profit     2,083       1,469       5,668       4,622  
Operating income     1,059       394       2,508       1,467  
Adjusted EBITDA     1,672       890       4,332       2,859  
                                 
Corporate and Other                                
Revenue   $ 301     $ 90     $ 493     $ 288  
Gross profit     275       63       412       (307 )
Operating loss     (1,343 )     (2,437 )     (5,136 )     (7,939 )
Adjusted EBITDA     (1,013 )     (2,030 )     (4,217 )     (6,957 )
                                 
Consolidated                                
Revenue   $ 9,907     $ 15,550     $ 28,488     $ 41,897  
Gross profit     3,247       5,201       8,849       12,936  
Operating (loss) income     (363 )     187       (3,522 )     (1,826 )
Adjusted EBITDA     792       1,304       (22 )     1,269  

Ballantyne Strong, Inc. and Subsidiaries

Reconciliation of Net Income (Loss) to Adjusted EBITDA

(In thousands)

(Unaudited)

    Three Months Ended September 30,  
    2020     2019  
    Strong Entertainment     Convergent     Corporate and Other     Discontinued Operations     Consolidated     Strong Entertainment     Convergent     Corporate and Other     Discontinued Operations     Consolidated  
Net income (loss)   $ 1,939     $ 1,000     $ (1,966 )   $ 4,673     $ 5,646     $ 1,265     $ 386     $ (3,316 )   $ (123 )   $ (1,788 )
Net income (loss) from discontinued operations                       (4,673 )     (4,673 )                       123       123  
Net income (loss) from continuing operations     1,939       1,000       (1,966 )           973       1,265       386       (3,316 )           (1,665 )
Interest expense, net     24       146       84             254       35       120       107             262  
Income tax expense (benefit)     488       (88 )     126             526       827       (96 )                 731  
Depreciation and amortization     226       613       46             885       226       492       54             772  
EBITDA     2,677       1,671       (1,710 )           2,638       2,353       902       (3,155 )           100  
Stock-based compensation expense                 239             239                   334             334  
Fair value adjustment to notes receivable                                   845                         845  
Equity method investment loss (income)     20             440             460       (287 )           783             496  
Loss on disposal of assets and impairment charges                 18             18       3                         3  
Foreign currency transaction loss (gain)     172       1                   173       (50 )     (16 )                 (66 )
Gain on property and casualty insurance recoveries     (2,736 )                       (2,736 )     (420 )                       (420 )
Severance and other                                         4       8             12  
Adjusted EBITDA   $ 133     $ 1,672     $ (1,013 )   $     $ 792     $ 2,444     $ 890     $ (2,030 )   $     $ 1,304  

    Nine Months Ended September 30,  
    2020     2019  
    Strong Entertainment     Convergent     Corporate and Other     Discontinued Operations     Consolidated     Strong Entertainment     Convergent     Corporate and Other     Discontinued Operations     Consolidated  
Net income (loss)   $ 918     $ 2,018     $ (5,969 )   $ 4,504     $ 1,471     $ 1,120     $ 1,085     $ (8,771 )   $ (2,790 )   $ (9,356 )
Net income (loss) from discontinued operations                       (4,504 )     (4,504 )                       2,790       2,790  
Net income (loss) from continuing operations     918       2,018       (5,969 )           (3,033 )     1,120       1,085       (8,771 )           (6,566 )
Interest expense, net     90       429       275             794       105       322       138             565  
Income tax expense     853       26       143             1,022       1,137       72       86             1,295  
Depreciation and amortization     688       1,804       142             2,634       665       1,387       162             2,214  
EBITDA     2,549       4,277       (5,409 )           1,417       3,027       2,866       (8,385 )           (2,492 )
Stock-based compensation expense                 724             724                   798             798  
Fair value adjustment to notes receivable                                   2,153                         2,153  
Equity method investment loss (income)     137             443             580       601             622             1,223  
Loss on disposal of assets and impairment charges                 18             18       66       1                   67  
Foreign currency transaction (gain) loss     (51 )     39                   (12 )     166       (12 )                 154  
Gain on property and casualty insurance recoveries     (2,850 )                       (2,850 )     (646 )                       (646 )
Severance and other     78       16       7             101             4       8             12  
Adjusted EBITDA   $ (137 )   $ 4,332     $ (4,217 )   $     $ (22 )   $ 5,367     $ 2,859     $ (6,957 )   $     $ 1,269  

Sierra Wireless Reports Third Quarter 2020 Results

Sierra Wireless Reports Third Quarter 2020 Results

VANCOUVER, British Columbia–(BUSINESS WIRE)–
Sierra Wireless, Inc. (NASDAQ: SWIR) (TSX: SW) today reported results for its third quarter ended September 30, 2020. All results are reported in U.S. dollars and are prepared in accordance with United States generally accepted accounting principles (GAAP), except as otherwise indicated below.

“We are on-track to complete the sale of our Automotive product line and expect the deal to close in the coming weeks. Our Continuing Operations in the Third Quarter, excluding the Automotive product line being divested, improved sequentially with Recurring and Other Services revenue up 11% sequentially and 22% year-over-year,” said Kent Thexton, President and CEO. “Combining revenue from our Continuing Operations with the discontinued Automotive product line, total revenue in the Third Quarter was $180.3 million compared to $174.0 million the prior year. Going forward, we are improving the Company’s operating efficiency and we have announced and are implementing a series of cost reduction initiatives.”

Revenue, including our Automotive Business, for the third quarter of 2020 was $180.3 million compared to $174.0 million in the third quarter of 2019, an increase of 3.6% in a challenging environment. Revenue, excluding our Automotive Business, for the third quarter of 2020 was $113.4 million compared to $136.7 million in the third quarter of 2019, a decrease of 17.1%. Revenue, excluding Automotive was up 1.5% sequentially from Q2 2020. Our transformation to an IoT Solutions company is progressing well with record recurring revenue design wins year to date and increasing device design wins. Additionally, in our Enterprise Networking we are seeing strong growth in our opportunities pipeline.

Quarterly revenue for our two business segments was as follows:

(i)

Revenue from IoT Solutions was $79.1 million in the third quarter of 2020, a decrease of 15.4% compared to $93.4 million in the third quarter of 2019 due to lower hardware sales in Enterprise gateway products and IoT Solutions modules driven by the impact of COVID-19, the economic impact on energy, sales & payment and public safety, competitive pressure in hardware only segments, and a transition to lower device ASPs with the increasing sales of LPWA technologies. Within this segment we had solid year-over-year recurring and other service revenue growth of 21.6% driven by growth in connected devices.

 

(ii)

Revenue from Embedded Broadband, excluding our Automotive Business, was $34.3 million in the third quarter of 2020, a decrease of 20.8% compared to $43.3 million in the third quarter of 2019, reflecting lower mobile computing and networking sales due to previously communicated design losses of two higher-margin computing customers.

Recurring and other services revenue in the third quarter of 2020 was $29.8 million, representing 26.3% of consolidated revenue and Product revenue was $83.6 million, representing 73.7% of consolidated revenue.

In accordance with U.S. GAAP, the results of operations of the Automotive Business are reported as discontinued operations in our consolidation statements of operations and comprehensive earnings (loss) for each of the three and nine months periods ended September 30, 2020 and 2019.

GAAP:

  • Gross margin, excluding our Automotive Business, was $39.5 million, or 34.8% of revenue, in the third quarter of 2020 compared to $49.6 million, or 36.3% of revenue, in the third quarter of 2019.
  • Operating expenses, excluding our Automotive Business, were $57.2 million in the third quarter of 2020 compared to $62.5 million in the third quarter of 2019. In the third quarter of 2020, we recorded government grants under the Canada Emergency Wage Subsidy (CEWS) of $5.6 million and other COVID-19 related subsidies of $0.7 million, totaling $6.3 million.
  • Loss from operations, which excludes our Automotive Business, was $17.8 million compared to $12.8 million in the third quarter of 2019.
  • Net loss from continuing operations, which excludes our Automotive Business, was $14.5 million, or loss of $0.40 per diluted share, compared to net loss of $19.8 million, or loss of $0.55 per diluted share, in the third quarter of 2019.
  • Net loss, which includes our Automotive Business, was $12.0 million, or loss of $0.33 per diluted share, compared to $20.2 million, or loss of $0.56 per diluted share, in the third quarter of 2019.
  • Short-term borrowings and long-term debt were $34.4 million as at September 30, 2020 compared to $15.0 million as at June 30, 2020.

NON-GAAP(1) Results Including Discontinued Operations (Automotive Business):

  • Total revenue was $180.3 million compared to $174.0 million in the third quarter of 2019.
  • Gross margin in the third quarter of 2020 was 27.3% compared to 31.7% in the third quarter of 2019.
  • Adjusted EBITDA was a loss of $0.4 million compared to earnings of $6.3 million in the third quarter of 2019.
  • Net loss was $7.1 million, or loss of $0.19 per diluted share, compared to net earnings of $1.0 million, or earnings of $0.03 per diluted share, in the third quarter of 2019.

NON-GAAP(1) Results Excluding Discontinued Operations (Automotive Business):

  • Gross margin was 34.7% compared to 36.3% in the third quarter of 2019.
  • Adjusted EBITDA was a loss of $7.4 million compared to earnings of $3.5 million in the third quarter of 2019.
  • Loss from operations was $11.8 million compared to $0.3 million in the third quarter of 2019.
  • Net loss from continuing operations was $12.0 million, or loss of $0.33 per share, compared to $0.3 million, or loss of $0.01 per share, in the third quarter of 2019.

(1) See “Non-GAAP Financial Measures” and “Reconciliation of GAAP and Non-GAAP Results by Quarter” below.

Cash, cash equivalents and restricted cash (including cash held for sale) at the end of the third quarter of 2020 was $72.0 million, representing an increase of $9.5 million from the end of the second quarter of 2020. The increase in cash was primarily driven by additional borrowings under our credit facility, offset by cash flow used in operating activities and capital expenditure. Our cash flow from operating activities were negatively impacted by the unwinding of our receivables factoring program related to the Automotive business prior to the completion of the divestiture.

Credit Facilities

During the third quarter, we entered into a Cdn$12.5M term loan agreement with Canadian Imperial Bank of Commerce (“CIBC”) backed by the Canadian Government under the Business Credit Availability Program to provide for additional liquidity to the Company.

Financial Guidance

The impact of the COVID-19 pandemic on our global business continues to remain uncertain. While we continue to evaluate the effects of COVID-19 on our business, the overall severity and duration of adverse impacts related to COVID-19 on our business, financial condition, cash flows and/or results of operations for the fourth quarter 2020 and beyond cannot be reasonably estimated at this time. The ultimate size of the impact of the COVID-19 pandemic on our business will depend on future developments which cannot be currently predicted.

Given these conditions, we continue not to provide guidance although we are seeing continued business improvements. In conjunction with the recently announced divestiture of the embedded automotive business, we have begun to initiate actions to reduce operating expenses by approximately $25 to $30 million on an annualized basis to rightsize the remaining business and improve ongoing earnings and cash flows.

We will continue to monitor the effects of COVID-19 on our business.

This non-GAAP guidance constitutes “forward-looking statements” within the meaning of applicable securities laws and reflects current business indicators and expectations. These statements are based on management’s current beliefs and assumptions, which could prove to be significantly incorrect. Forward-looking statements, particularly those that relate to longer periods of time, are subject to substantial known and unknown risks and uncertainties that could cause actual events or results to differ significantly from those expressed or implied by our forward-looking statements, including those described in our regulatory filings. See “Cautionary Note Regarding Forward-Looking Statements” below.

Non-GAAP Financial Measures

We disclose these non-GAAP financial measures as we believe they provide useful information to investors and analysts to assist them in their evaluation of our operating results and to assist in comparisons from one period to another. Readers are cautioned that non-GAAP financial measures do not have any standardized meaning prescribed by U.S. GAAP and therefore may not be comparable to similar measures presented by other companies.

Non-GAAP gross margin excludes the impact of stock-based compensation expense and related social taxes and certain other non-recurring costs or recoveries.

Non-GAAP earnings (loss) from operations includes allocation of realized gains or losses on forward contracts and excludes the impact of stock-based compensation expense and related social taxes, acquisition-related amortization, acquisition-related and integration costs, restructuring costs, impairment, government grants related to COVID-19 relief and certain other non-recurring costs or recoveries.

Non-GAAP income tax expense includes certain tax adjustments and taxes on acquisition-related amortization, acquisition-related and integration costs, restructuring costs, other non-recurring costs and foreign exchange.

Non-GAAP net earnings (loss) and non-GAAP net earnings (loss) per share exclude the impact of foreign exchange gains or losses on translation of certain balance sheet accounts, foreign exchange gains or losses on forward contracts and certain tax adjustments.

Non-GAAP net earnings (loss) from continuing operations is equal to non-GAAP earnings (loss) from operations as described above, excluding operating results of our Automotive Business and excluding the impact of foreign exchange gains or losses on translation of certain balance sheet accounts, foreign exchange gains or losses on forward contracts and certain tax adjustments.

Non-GAAP net earnings (loss) from discontinued operations is equal to non-GAAP earnings (loss) from operations as described above pertaining to our Automotive Business, excluding the impact of foreign exchange gains or losses on translation of certain balance sheet accounts, foreign exchange gains or losses on forward contracts and certain tax adjustments.

Adjusted EBITDA is defined as net earnings (loss) plus stock-based compensation expense and related social taxes, acquisition-related and integration costs, restructuring cost, impairment, certain other non-recurring costs or recoveries, amortization, foreign exchange gains or losses on translation of certain balance sheet accounts, unrealized foreign exchange gains or losses on forward contracts, interest, government grants related to COVID-19 relief and income tax expense. Adjusted EBITDA is a metric used by investors and analysts for valuation purposes and is an important indicator of our operating performance and our ability to generate liquidity through operating cash flow that will fund future working capital needs and fund future capital expenditures.

Adjusted EBITDA (continuing and discontinued) is equal to the Adjusted EBITDA as defined above including operating results of our Automotive Business.

We use the above-noted non-GAAP financial measures for planning purposes and to allow us to assess the performance of our business before including the impacts of the items noted above as they affect the comparability of our financial results. These non-GAAP measures are reviewed regularly by management and the Board of Directors as part of the ongoing internal assessment of our operating performance. We also use non-GAAP earnings from operations as one component in determining short-term incentive compensation for management employees.

Conference call and webcast details

Sierra Wireless President and CEO, Kent Thexton, and CFO, Samuel Cochrane, will host a conference call and webcast with analysts and investors to review the results on Thursday November 12, 2020, at 6:00 PM Eastern time (3:00 PM Pacific time). A live slide presentation will be available for viewing during the call from the link provided below.

To participate in this conference call, please dial the following number approximately ten minutes prior to the start of the call:

  • Toll-free (Canada and US): 1-877-201-0168
  • Alternate number: 1-647-788-4901
  • Conference ID: 7390518

To access the webcast, please follow the link below:

Sierra Wireless Q3 2020 Conference Call and Webcast

If the above link does not work, please copy and paste the following URL into your browser:

https://onlinexperiences.com/Launch/QReg/ShowUUID=E5E7D527-646D-4053-9906-4A5774F72BE2.

The webcast will remain available at the above link for one year following the call.

Cautionary Note Regarding Forward-Looking Statements

Certain statements and information in this press release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws (collectively, “forward-looking statements”) and may include statements and information relating to our 2020 corporate update; financial guidance for our fiscal year 2020; the impact of COVID-19 on customer demand, our supply chain, manufacturing capacity, our ability to meet customer demand and our financial results; expectations regarding post-COVID-19 recovery; expectations regarding the Company’s cost savings initiatives; anticipated benefits of our recently announced divestiture of the automotive product line (the “Sale Transaction”) and the Company’s exit from automotive applications; the anticipated timing of the closing of the Sale Transaction; expectations regarding movement of employees pursuant to the Sale Transaction; our business outlook for the short and long term; statements regarding our strategy, plans, goals, objectives, expectations and future operating performance; the Company’s liquidity and capital resources; the Company’s financial and operating objectives and strategies to achieve them; general economic conditions; estimates of our expenses, future revenues, financial results and capital requirements; our expectations regarding the legal proceedings we are involved in; statements with respect to the Company’s estimated working capital; expectations with respect to the adoption of Internet of Things (“IoT”) solutions; expectations regarding trends and growth in the IoT market and wireless module market; expectations regarding product and price competition from other wireless device manufacturers and solution providers; our ability to implement effective control procedures; and expectations regarding the launch of fifth generation cellular embedded modules and gateways. Forward-looking statements are provided to help you understand our views of our short and long term plans, expectations and prospects. We caution you that forward-looking statements may not be appropriate for other purposes.

Forward-looking statements:

  • Typically include words and phrases about the future such as “outlook”, “will”, “may”, “expects”, “is expected”, “anticipates”, “believes”, “plans”, “projects”, “estimates”, “assumes”, “intends”, “strategy”, “goals”, “objectives”, “potential”, “possible”, or variations thereof.
  • Are not promises or guarantees of future performance. They represent our current views and may change significantly.
  • Are based on a number of material assumptions, including, but not limited to, those listed below, which could prove to be significantly incorrect:

    • the scope and duration of the COVID-19 pandemic and its impact on our business;
    • our ability to return to normal operations after the COVID-19 pandemic has subsided;
    • expected component supply constraints and manufacturing capacity;
    • customer demand and our ability to continue to sell our products and services in the expected quantities at the expected prices and expected times;
    • our ability to realize the anticipated benefits of the Sale Transaction;
    • our ability to effect and to realize the anticipated benefits of our business transformation initiatives, and the timing thereof;
    • our ability to develop, manufacture and sell new products and services that meet the needs of our customers and gain commercial acceptance;
    • expected macro-economic business conditions;
    • expected cost of sales;
    • our ability to win new business;
    • our ability to integrate acquired businesses and realize expected benefits;
    • our ability to renew or obtain credit facilities when required;
    • expected deployment of next generation networks by wireless network operators;
    • our operations not being adversely disrupted by other developments, operating, cyber security, litigation, or regulatory risks; and
    • expected tax and foreign exchange rates.
  • Are based on our management’s current expectations and we caution investors that forward-looking statements, particularly those that relate to longer periods of time, are subject to substantial known and unknown material risks and uncertainties. Many factors could cause our actual results, achievements and developments in our business to differ significantly from those expressed or implied by our forward-looking statements, including without limitation, the following factors. These risk factors and others are discussed in our Annual Information Form and Management’s Discussion and Analysis of Financial Condition and Results of Operations, which may be found on SEDAR at www.sedar.com and on EDGAR at www.sec.gov and in our other regulatory filings with the Securities and Exchange Commission in the United States and the provincial securities commissions in Canada:

    • prolonged negative impact from COVID-19;
    • our access to capital if required;
    • competition from new or established competitors or from those with greater resources;
    • natural catastrophes or public health epidemics could impact customer demand, result in production disruption and impact our ability to meet customer demand or capacity to continue critical operations;
    • risks that the Sale Transaction may not be completed in a timely manner or at all, which may adversely affect our business and the price of our common shares;
    • failure to satisfy the conditions to the consummation of the Sale Transaction, including any required approvals;
    • risks that the Sale Transaction may fail to realize the expected benefits;
    • the loss of, or significant demand fluctuations from, any of our significant customers;
    • our financial results being subject to fluctuation;
    • our business transformation initiatives may result in disruptions to our business and may not achieve the anticipated benefits;
    • our ability to respond to changing technology, industry standards and customer requirements;
    • failures of our products or services due to design flaws and errors, component quality issues, manufacturing defects, network service interruptions, cyber-security vulnerabilities or other quality issues;
    • deterioration in macro-economic conditions could adversely affect our operating results and financial conditions;
    • our ability to attract or retain key personnel and the impact of organizational changes on our business;
    • cyber-attacks or other breaches of our information technology security;
    • risks related to the transmission, use and disclosure of user data and personal information;
    • disruption of, and demands on, our ongoing business and diversion of management’s time and attention in connection with acquisitions or divestitures;
    • risks that the acquisition of the M2M Group or our investments and partnerships may fail to realize the expected benefits;
    • risks related to infringement on intellectual property rights of others;
    • our ability to obtain necessary rights to use software or components supplied by third parties;
    • our ability to enforce our intellectual property rights;
    • our reliance on single source suppliers for certain components used in our products;
    • our dependence on a limited number of third party manufacturers;
    • unanticipated costs associated with litigation or settlements;
    • our dependence on mobile network operators to promote and offer acceptable wireless data services;
    • risks related to contractual disputes with counterparties;
    • risks related to governmental regulation;
    • risks inherent in foreign jurisdictions; and
    • risks related to tariffs or other trade restrictions.

About Sierra Wireless

Sierra Wireless (NASDAQ: SWIR) (TSX: SW) is the leading IoT solutions provider that combines devices, network services and software to unlock value in the connected economy. Companies globally are adopting IoT to improve operational efficiency, create better customer experiences, improve their business models and create new revenue streams. Whether it is a solution to help a business securely connect edge devices to the cloud, or a software/API solution to help manage processes associated with billions of connected assets, or a platform to extract real-time data to make the best business decisions, Sierra Wireless will work with you to create the right industry-specific solution for your next IoT endeavor. Sierra Wireless has more than 1,300 employees globally and operates R&D centers in North America, Europe and Asia. For more information, visit www.sierrawireless.com.

“Sierra Wireless” is a registered trademark of Sierra Wireless. Other product or service names mentioned herein may be the trademarks of their respective owners.

SIERRA WIRELESS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE EARNINGS (LOSS)

(In thousands of U.S. dollars, except where otherwise stated)

(unaudited)

 

 

Three months ended

September 30,

 

Nine months ended

September 30,

 

2020

 

2019

 

2020

 

2019

Revenue

 

 

 

 

 

 

 

IoT Solutions

$

79,093

 

 

$

93,439

 

 

$

239,719

 

 

$

286,871

 

Embedded Broadband

34,278

 

 

43,256

 

 

88,391

 

 

135,298

 

 

113,371

 

 

136,695

 

 

328,110

 

 

422,169

 

Cost of sales

 

 

 

 

 

 

 

IoT Solutions

49,466

 

 

58,236

 

 

151,543

 

 

180,378

 

Embedded Broadband

24,453

 

 

28,835

 

 

61,182

 

 

89,065

 

 

73,919

 

 

87,071

 

 

212,725

 

 

269,443

 

Gross margin

39,452

 

 

49,624

 

 

115,385

 

 

152,726

 

Expenses

 

 

 

 

 

 

 

Sales and marketing

20,072

 

 

22,286

 

 

64,818

 

 

66,115

 

Research and development

17,699

 

 

18,796

 

 

61,151

 

 

57,974

 

Administration

11,199

 

 

11,496

 

 

35,111

 

 

35,854

 

Restructuring

3,089

 

 

4,588

 

 

3,940

 

 

24,011

 

Acquisition-related and integration

140

 

 

291

 

 

325

 

 

700

 

Amortization

5,040

 

 

5,013

 

 

15,755

 

 

15,198

 

 

57,239

 

 

62,470

 

 

181,100

 

 

199,852

 

Loss from operations

(17,787

)

 

(12,846

)

 

(65,715

)

 

(47,126

)

Foreign exchange gain (loss)

3,659

 

 

(2,929

)

 

4,269

 

 

(2,885

)

Other expense

(988

)

 

(122

)

 

(1,463

)

 

(196

)

Loss before income taxes

(15,116

)

 

(15,897

)

 

(62,909

)

 

(50,207

)

Income tax expense (recovery)

(633

)

 

3,864

 

 

(3,925

)

 

9,140

 

Net loss from continuing operations

$

(14,483

)

 

$

(19,761

)

 

$

(58,984

)

 

$

(59,347

)

Net earnings (loss) from discontinued operations

$

2,456

 

 

$

(460

)

 

$

8,687

 

 

$

(273

)

Net loss

$

(12,027

)

 

$

(20,221

)

 

$

(50,297

)

 

$

(59,620

)

Other comprehensive gain (loss):

 

 

 

 

 

 

 

Foreign currency translation adjustments, net of taxes of $nil

2,670

 

 

(3,727

)

 

2,122

 

 

(7,247

)

Comprehensive loss

$

(9,357

)

 

$

(23,948

)

 

$

(48,175

)

 

$

(66,867

)

 

 

 

 

 

 

 

 

Basic and diluted net earnings (loss) per share (in dollars)

 

 

 

 

 

 

 

Continuing operations

$

(0.40

)

 

$

(0.55

)

 

$

(1.62

)

 

$

(1.64

)

Discontinued operations

0.07

 

 

(0.01

)

 

0.24

 

 

(0.01

)

 

$

(0.33

)

 

$

(0.56

)

 

$

(1.38

)

 

$

(1.65

)

Weighted average number of shares outstanding (in thousands)

 

 

 

 

 

 

 

Basic

36,417

 

 

36,179

 

 

36,345

 

 

36,147

 

Diluted

36,417

 

 

36,179

 

 

36,345

 

 

36,147

 

SIERRA WIRELESS, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands of U.S. dollars, except where otherwise stated)

(unaudited)

 

 

September 30, 2020

 

December 31, 2019

Assets

 

 

 

Current assets

 

 

 

Cash and cash equivalents

$

63,483

 

 

$

71,164

 

Restricted cash

3,029

 

 

3,629

 

Accounts receivable, net of allowance of $3,772 (December 31, 2019 – $3,892)

69,972

 

 

94,491

 

Inventories

35,172

 

 

36,334

 

Prepaids and other

12,193

 

 

10,858

 

Assets held for sale

161,204

 

 

67,586

 

 

345,053

 

 

284,062

 

Property and equipment, net

28,505

 

 

27,577

 

Operating lease right-of-use assets

21,185

 

 

25,466

 

Intangible assets, net

76,717

 

 

70,072

 

Goodwill

167,769

 

 

154,381

 

Deferred income taxes

1,883

 

 

1,779

 

Other assets

9,821

 

 

9,982

 

Long-term assets held for sale

 

 

66,021

 

 

$

650,933

 

 

$

639,340

 

Liabilities

 

 

 

Current liabilities

 

 

 

Short-term borrowings

$

25,000

 

 

$

 

Current portion of long-term debt

235

 

 

 

Accounts payable and accrued liabilities

154,215

 

 

149,596

 

Deferred revenue

9,331

 

 

9,190

 

Liabilities held for sale

34,392

 

 

25,380

 

 

223,173

 

 

184,166

 

Long-term obligations

44,845

 

 

43,407

 

Operating lease liabilities

20,059

 

 

25,154

 

Long-term debt

9,148

 

 

 

Deferred income taxes

10,283

 

 

4,921

 

Long-term liabilities held for sale

 

 

367

 

 

307,508

 

 

258,015

 

Equity

 

 

 

Shareholders’ equity

 

 

 

Common stock: no par value; unlimited shares authorized; issued and outstanding:

36,491,352 shares (December 31, 2019 – 36,233,361 shares)

440,003

 

 

435,532

 

Preferred stock: no par value; unlimited shares authorized;

issued and outstanding: nil shares

 

 

 

Treasury stock: at cost; 43,979 shares (December 31, 2019 – 44,487 shares)

(508

)

 

(370

)

Additional paid-in capital

44,933

 

 

38,212

 

Retained deficit

(129,909

)

 

(78,833

)

Accumulated other comprehensive loss

(11,094

)

 

(13,216

)

 

343,425

 

 

381,325

 

 

$

650,933

 

 

$

639,340

 

SIERRA WIRELESS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands of U.S. dollars)

(unaudited)

 

 

Three months ended

September 30,

 

Nine months ended

September 30,

 

2020

 

2019

 

2020

 

2019

Cash flows provided by (used in):

 

 

 

 

 

 

 

Operating activities

 

 

 

 

 

 

 

Net loss

$

(12,027

)

 

$

(20,221

)

 

$

(50,297

)

 

$

(59,620

)

Items not requiring (providing) cash

 

 

 

 

 

 

 

Amortization

8,269

 

 

8,115

 

 

25,292

 

 

24,604

 

Stock-based compensation

5,667

 

 

3,869

 

 

12,125

 

 

11,129

 

Deferred income taxes

153

 

 

3,766

 

 

144

 

 

8,804

 

Unrealized foreign exchange (gain) loss

(4,278

)

 

4,056

 

 

(3,917

)

 

2,080

 

Other

54

 

 

62

 

 

(153

)

 

648

 

Changes in non-cash working capital

 

 

 

 

 

 

 

Accounts receivable

(27,524

)

 

19,811

 

 

(1,236

)

 

37,809

 

Inventories

9,330

 

 

(4,357

)

 

(2,225

)

 

(9,976

)

Prepaids and other

8,273

 

 

(1,982

)

 

2,614

 

 

(7,500

)

Accounts payable and accrued liabilities

4,589

 

 

(7,102

)

 

10,622

 

 

497

 

Deferred revenue

(188

)

 

1,961

 

 

(1,404

)

 

4,679

 

Cash flows provided by (used in) operating activities

(7,682

)

 

7,978

 

 

(8,435

)

 

13,154

 

Investing activities

 

 

 

 

 

 

 

Additions to property and equipment

(2,416

)

 

(3,672

)

 

(12,143

)

 

(11,803

)

Additions to intangible assets

(503

)

 

(1,585

)

 

(1,974

)

 

(2,978

)

Proceeds from sale of property and equipment

28

 

 

3

 

 

252

 

 

87

 

Proceeds from sale of iTank business

 

 

 

 

 

 

500

 

Acquisition of M2M Group, net of cash acquired

 

 

 

 

(18,391

)

 

 

Cash flows used in investing activities

(2,891

)

 

(5,254

)

 

(32,256

)

 

(14,194

)

Financing activities

 

 

 

 

 

 

 

Issuance of common shares

883

 

 

160

 

 

883

 

 

327

 

Purchase of treasury shares for RSU distribution

(544

)

 

(59

)

 

(764

)

 

(326

)

Taxes paid related to net settlement of equity awards

(565

)

 

(110

)

 

(1,191

)

 

(855

)

Decrease in other long-term obligations

(47

)

 

(191

)

 

(234

)

 

(405

)

Proceeds from short-term borrowings

10,000

 

 

 

 

25,000

 

 

 

Proceeds from long-term debt

9,383

 

 

 

 

9,383

 

 

 

Cash flows provided by (used in) financing activities

19,110

 

 

(200

)

 

33,077

 

 

(1,259

)

Effect of foreign exchange rate changes on cash and cash equivalents

978

 

 

(393

)

 

503

 

 

123

 

Cash, cash equivalents and restricted cash, increase (decrease) in the period

9,515

 

 

2,131

 

 

(7,111

)

 

(2,176

)

Cash, cash equivalents and restricted cash, beginning of period

62,457

 

 

84,990

 

 

79,083

 

 

89,297

 

Cash, cash equivalents and restricted cash, end of period

$

71,972

 

 

$

87,121

 

 

$

71,972

 

 

$

87,121

 

Cash, cash equivalents and restricted cash are comprised of:

 

 

 

 

 

 

 

Cash, cash equivalents and restricted cash

66,512

 

 

82,874

 

 

66,512

 

 

82,874

 

Cash and cash equivalents classified as held for sale

5,460

 

 

4,247

 

 

5,460

 

 

4,247

 

Cash, cash equivalents and restricted cash, end of period

$

71,972

 

 

$

87,121

 

 

$

71,972

 

 

$

87,121

 

SIERRA WIRELESS, INC.

RECONCILIATION OF GAAP AND NON-GAAP RESULTS BY QUARTER

 

(in thousands of U.S. dollars, except where

2020

 

 

2019

 

otherwise stated)

Q3

Q2

Q1

 

 

Total

Q4

Q3

Q2

Q1

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross margin – GAAP

$

39,452

 

$

41,008

 

$

34,925

 

 

 

$

197,486

 

$

44,760

 

$

49,624

 

$

52,981

 

$

50,121

 

 

Stock-based compensation and related social taxes

91

 

65

 

49

 

 

 

167

 

20

 

44

 

44

 

59

 

 

Realized losses on hedge contracts

1

 

(74

)

(1

)

 

 

(4

)

1

 

 

(2

)

(3

)

 

Other non-recurring costs

(168

)

 

 

 

 

 

 

 

 

 

 

Gross margin – Non-GAAP

$

39,376

 

$

40,999

 

$

34,973

 

 

 

$

197,649

 

$

44,781

 

$

49,668

 

$

53,023

 

$

50,177

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (loss) from operations – GAAP

$

(17,787

)

$

(20,125

)

$

(27,803

)

 

 

$

(64,254

)

$

(17,128

)

$

(12,846

)

$

(24,547

)

$

(9,733

)

 

Stock-based compensation and related social taxes

5,085

 

3,256

 

3,200

 

 

 

12,815

 

1,773

 

3,763

 

3,979

 

3,300

 

 

Acquisition-related and integration

140

 

185

 

 

 

 

974

 

274

 

291

 

314

 

95

 

 

Restructuring

3,089

 

245

 

606

 

 

 

26,262

 

2,251

 

4,588

 

18,083

 

1,340

 

 

COVID-19 government relief

(6,298

)

 

 

 

 

 

 

 

 

 

 

Other nonrecurring costs

299

 

152

 

87

 

 

 

2,903

 

795

 

279

 

662

 

1,167

 

 

Impairment

 

 

 

 

 

877

 

877

 

 

 

 

 

Realized gains (losses) on hedge contracts

87

 

(411

)

(98

)

 

 

(187

)

81

 

24

 

(183

)

(109

)

 

Acquisition-related amortization

3,555

 

3,886

 

3,889

 

 

 

14,514

 

3,593

 

3,610

 

3,624

 

3,687

 

 

Earnings (loss) from operations – Non-GAAP

$

(11,830

)

$

(12,812

)

$

(20,119

)

 

 

$

(6,096

)

$

(7,484

)

$

(291

)

$

1,932

 

$

(253

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net earnings (loss) from continuing operations – GAAP

$

(14,483

)

$

(17,291

)

$

(27,210

)

 

 

$

(74,663

)

$

(15,316

)

$

(19,761

)

$

(28,961

)

$

(10,625

)

 

Stock-based compensation and related social

taxes, restructuring, impairment, acquisition-

related, integration, COVID-19 government

relief and other non-recurring costs

(recoveries)

2,315

 

3,838

 

3,893

 

 

 

43,831

 

5,970

 

8,921

 

23,038

 

5,902

 

 

Amortization

8,030

 

7,823

 

7,726

 

 

 

30,233

 

7,849

 

7,378

 

7,355

 

7,651

 

 

Interest and other, net

988

 

283

 

192

 

 

 

307

 

111

 

122

 

105

 

(31

)

 

Foreign exchange loss (gain)

(3,572

)

(3,955

)

2,836

 

 

 

1,037

 

(1,580

)

2,953

 

(1,034

)

698

 

 

Income tax expense (recovery)

(633

)

427

 

(3,719

)

 

 

8,878

 

(262

)

3,864

 

5,160

 

116

 

 

Adjusted EBITDA

$

(7,355

)

$

(8,875

)

$

(16,282

)

 

 

$

9,623

 

$

(3,228

)

$

3,477

 

$

5,663

 

$

3,711

 

 

Amortization (exclude acquisition-related amortization)

(4,475

)

(3,937

)

(3,837

)

 

 

(15,719

)

(4,256

)

(3,768

)

(3,731

)

(3,964

)

 

Interest and other, net

(988

)

(283

)

(192

)

 

 

(307

)

(111

)

(122

)

(105

)

31

 

 

Income tax expense – Non-GAAP

833

 

(69

)

1,023

 

 

 

146

 

677

 

69

 

(355

)

(245

)

 

Net earnings (loss) from continuing operations – Non-GAAP

$

(11,985

)

$

(13,164

)

$

(19,288

)

 

 

$

(6,257

)

$

(6,918

)

$

(344

)

$

1,472

 

$

(467

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net earnings (loss) from discontinued operations – GAAP

$

2,456

 

$

1,684

 

$

4,547

 

 

 

$

4,125

 

$

4,398

 

$

(460

)

$

785

 

$

(598

)

 

Stock-based compensation and related social

taxes, restructuring, impairment, acquisition-

related, integration, COVID-19 government

relief and other non-recurring costs

(recoveries)

3,344

 

555

 

33

 

 

 

2,277

 

87

 

1,799

 

220

 

171

 

 

Foreign exchange loss (gain)

46

 

10

 

35

 

 

 

72

 

(5

)

35

 

(3

)

45

 

 

Income tax expense (recovery)

(927

)

(165

)

(21

)

 

 

(522

)

(501

)

(9

)

(7

)

(5

)

 

Net earnings (loss) from discontinued operations – NON-GAAP

$

4,919

$

2,084

 

$

4,594

 

 

 

$

5,952

 

$

3,979

 

$

1,365

 

$

995

 

$

(387

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2020

 

 

2019

 

 

Q3

Q2

Q1

 

 

Total

Q4

Q3

Q2

Q1

 

Net earnings (loss) – GAAP

$

(12,027

)

$

(15,607

)

$

(22,663

)

 

 

$

(70,538

)

$

(10,918

)

$

(20,221

)

$

(28,176

)

$

(11,223

)

 

Net earnings (loss) – NON-GAAP

$

(7,066

)

$

(11,080

)

$

(14,694

)

 

 

$

(305

)

$

(2,939

)

$

1,021

 

$

2,467

 

$

(854

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted net earnings (loss) per share

 

 

 

 

 

 

 

 

 

 

 

GAAP – (in dollars per share)

$

(0.33

)

$

(0.43

)

$

(0.62

)

 

 

$

(1.95

)

$

(0.30

)

$

(0.56

)

$

(0.78

)

$

(0.31

)

 

Non-GAAP – (in dollars per share)

$

(0.19

)

$

(0.30

)

$

(0.41

)

 

 

$

(0.01

)

$

(0.08

)

$

0.03

 

$

0.07

 

$

(0.02

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net earnings (loss) – GAAP

$

(12,027

)

$

(15,607

)

$

(22,663

)

 

 

$

(70,538

)

$

(10,918

)

$

(20,221

)

$

(28,176

)

$

(11,223

)

 

Stock-based compensation and related social

taxes, restructuring, impairment, acquisition-

related, integration and other non-recurring

costs (recoveries)

11,957

 

4,393

 

3,926

 

 

 

46,108

 

6,057

 

10,720

 

23,258

 

6,073

 

 

COVID-19 government relief

(6,298

)

 

 

 

 

 

 

 

 

 

 

Amortization

8,269

 

8,538

 

8,485

 

 

 

33,177

 

8,573

 

8,115

 

8,118

 

8,371

 

 

Interest expense and other, net

987

 

280

 

191

 

 

 

301

 

109

 

121

 

102

 

(31

)

 

Foreign exchange loss (gain)

(3,526

)

(3,945

)

2,871

 

 

 

1,109

 

(1,585

)

2,988

 

(1,037

)

743

 

 

Income tax expense (recovery)

268

 

1,031

 

(1,978

)

 

 

10,920

 

90

 

4,577

 

5,657

 

596

 

 

Adjusted EBITDA (continuing and discontinued)

$

(370

)

$

(5,310

)

$

(9,168

)

 

 

$

21,077

 

$

2,326

 

$

6,300

 

$

7,922

 

$

4,529

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SIERRA WIRELESS, INC.

SEGMENTED RESULTS

Prior period results have been reclassified to conform to current period presentation

 
(In thousands of U.S. dollars,

2020

 

 

2019

except where otherwise

 

 

 

 

 

 

 

 

 

 

indicated)

Q3

Q2

Q1

 

 

Total

Q4

Q3

Q2

Q1

 

 

 

 

 

 

 

 

 

 

 

IoT Solutions

 

 

 

 

 

 

 

 

 

 

Revenue

$

79,093

 

$

81,836

 

$

78,790

 

 

 

$

377,808

 

$

90,937

 

$

93,439

 

$

99,145

 

$

94,287

 

Gross margin

 

 

 

 

 

 

 

 

 

 

– GAAP

$

29,627

 

$

30,538

 

$

28,011

 

 

 

$

140,158

 

$

33,665

 

$

35,203

 

$

36,811

 

$

34,479

 

– Non-GAAP

$

29,594

 

$

30,533

 

$

28,035

 

 

 

$

140,222

 

$

33,676

 

$

35,203

 

$

36,833

 

$

34,510

 

Gross margin %

 

 

 

 

 

 

 

 

 

 

– GAAP

37.5%

37.3%

35.6%

 

 

37.1%

37.0%

37.7%

37.1%

36.6%

– Non-GAAP

37.4%

37.3%

35.6%

 

 

37.1%

37.0%

37.7%

37.2%

36.6%

 

 

 

 

 

 

 

 

 

 

 

Embedded Broadband

 

 

 

 

 

 

 

 

 

 

Revenue

$

34,278

 

$

29,882

 

$

24,231

 

 

 

$

169,468

 

$

34,170

 

$

43,256

 

$

46,520

 

$

45,522

 

Gross margin

 

 

 

 

 

 

 

 

 

 

– GAAP

$

9,825

 

$

10,470

 

$

6,914

 

 

 

$

57,328

 

$

11,095

 

$

14,421

 

$

16,170

 

$

15,642

 

– Non-GAAP

$

9,782

 

$

10,466

 

$

6,938

 

 

 

$

57,427

 

$

11,105

 

$

14,465

 

$

16,190

 

$

15,667

 

Gross margin %

 

 

 

 

 

 

 

 

 

 

– GAAP

28.7%

35.0%

28.5%

 

 

33.8%

32.5%

33.3%

34.8%

34.4%

– Non-GAAP

28.5%

35.0%

28.6%

 

 

33.9%

32.5%

33.4%

34.8%

34.4%

Total

 

 

 

 

 

 

 

 

 

 

Revenue

$

113,371

 

$

111,718

 

$

103,021

 

 

 

$

547,276

 

$

125,107

 

$

136,695

 

$

145,665

 

$

139,809

 

Gross margin

 

 

 

 

 

 

 

 

 

 

– GAAP

$

39,452

 

$

41,008

 

$

34,925

 

 

 

$

197,486

 

$

44,760

 

$

49,624

 

$

52,981

 

$

50,121

 

– Non-GAAP

$

39,376

 

$

40,999

 

$

34,973

 

 

 

$

197,649

 

$

44,781

 

$

49,668

 

$

53,023

 

$

50,177

 

Gross margin %

 

 

 

 

 

 

 

 

 

 

– GAAP

34.8%

36.7%

33.9%

 

 

36.1%

35.8%

36.3%

36.4%

35.8%

– Non-GAAP

34.7%

36.7%

33.9%

 

 

36.1%

35.8%

36.3%

36.4%

35.9%

Revenue by Type:

 

 

 

 

 

 

 

 

 

 

Product

$

83,560

 

$

84,820

 

$

76,308

 

 

 

$

449,063

 

$

99,024

 

$

112,177

 

$

120,859

 

$

117,003

 

Recurring and other services

$

29,811

 

$

26,898

 

$

26,713

 

 

 

$

98,213

 

$

26,083

 

$

24,518

 

$

24,806

 

$

22,806

 

 

 

 

 

 

 

 

 

 

 

 

 

Investor and Media:

David Climie, Investor Relations

[email protected]

Investor:

Samuel Cochrane, Chief Financial Officer

[email protected]

KEYWORDS: United States North America Canada California

INDUSTRY KEYWORDS: Technology Mobile/Wireless Hardware Telecommunications

MEDIA:

Logo
Logo